Evelyn Pringle September 10, 2007
Alaska attorney Jim Gottstein has issued subpoenas for the discovery of any suppressed data on the atypical antipsychotic drugs Zyprexa, Risperdal, and Seroquel which he says is necessary before a Forced Drugging Petition can possibly be considered for approval for a client he is representing.
Mr Gottstein contends that the information sought from Eli Lilly, AstraZeneca and Johnson & Johnson will show that the side effects of the drugs were well-established by the drug makers' own clinical trials and therefore, his client should not be forced to take such medications against his will.
According to Mr Gottstein, various off-label combinations of Risperdal, Seroquel, Zyprexa and the anti-seizure drug Depakote have been administered to his client in the past, over his objections, which have not been FDA approved as safe or effective for use in any patient.
The subpoena issued to Sidney Taurel, Chairman and CEO of Eli Lilly calls for the production of the same documents requested by Congressman Henry Waxman (D-Cal), as chairman of the House Oversight and Government Reform Committee, on March 1, 2007.
On March 1, 2007, Rep Waxman sent letters to both Lilly and AstraZeneca, requesting extensive information about their marketing practices. The letter to Lilly states in part, "Allegations have been raised that Eli Lilly misled physicians and inappropriately promoted off-label uses of Zyprexa," and requests information relevant to these allegations.
The letter asks for a list of all Zyprexa trials, studies, or reports; all presentations given to employees who promoted Zyprexa; information shown to physicians; presentations related to prescribing patterns, continuing medical education, and off-label use; and all documents and correspondence related to funding for nonprofit professional organizations or consumer patient groups.
The letter to Astra basically asks for the same documents except that Rep Waxman asks for more information related to the physicians and authors involved in company sponsored studies on Seroquel and writing the reports.
However, Rep Waxman also asked Lilly to turn over a batch of documents that were kept under seal for years with a court order issued by a federal court in New York, but were provided to him by Attorney Gottstein in December 2006, which Rep Waxman subsequently returned to Lilly on December 21, 2006, to honor the court order.
Mr Gottstein originally obtained the documents by subpoenaing Dr David Egilman, who served as a plaintiffs expert witness in the Zyprexa Products Liability litigation, pending in the United States District Court in the Eastern District of New York (MDL 1596), for a case unrelated to the Products Liability case.
The MDL 1596 litigation involved tens of thousands of lawsuits filed by Zyprexa victims who alleged that Lilly illegally marketed the drug for off-label uses and concealed the serious side effects known to be associated with Zyprexa for a decade.
As soon as Mr Gottstein received the documents he provided copies to reporter, Alex Berenson, at the New York Times, and to a number of other journalists, patient rights activists and advocacy groups and several leading experts on psychotropic drugs.
Once a medication is approved to treat one condition, doctors may prescribe it off-label for other indications if they think it will be effective, but drug makers are barred by law from encouraging physicians to prescribe a drug for uses other than those listed on the FDA approved label. But in recent years, its a well-known fact that off-label promotion has become the industries primary marketing tool when it comes to psychiatric drugs.
"Off-label" use also includes treating an approved condition for a longer duration of time, or in combination with other drugs, or at a different dosage, or with a different patient population such children or the elderly, than are listed on the label.
Zyprexa (Lilly), Risperdal (J&J) and Seroquel (AstraZeneca) belong to a class of drugs known as "atypical" antipsychotics. The other atypical drug include Abilify (Bristol Meyers Squibb), Geodon (Pfizer) and Clozril (Novartis).
The drugs were FDA approved only to treat schizophrenia and the manic phase of bipolar disorder in adults and have never been approved for use in combination with each other.
The many lawsuits filed against Lilly allege that the company's off-label marketing campaigns included influencing doctors to prescribe the drug to millions of patients ranging from toddlers to the elderly for an exhaustive list of unapproved uses such as anxiety, sleep disruption, mood swings, post-partum depression, autism, attention deficit hyperactivity and dementia.
According to Harrisburg Pennsylvania psychiatrist, Dr Stefan Kruszewski, the atypical drugs can increase the risk of drastic weight gain, diabetes, pancreatitis, hypertension, heart attacks and stroke.
"The drugs can cause both a severe metabolic syndrome consisting of obesity, diabetes and cardiovascular problems," he explains, "at the same time that they cause the neurological side effects as the older antipsychotics such as akathesis, a severe restlessness and tardive dyskinesia an often irreversible movement disorder."
As an expert witness in the case, Dr Egilman reviewed the Lilly documents kept under seal by the court order and learned that Lilly had indeed engaged in a massive off-label marketing scheme to increase profits by encouraging doctors to prescribe the drug for unapproved uses and had concealed the drug's serious side effects.
As a physician, after learning what was in the documents and knowing the harm that was sure to come to patients who continued to take Zyprexa, Dr Egilman was clearly facing a major ethical dilemma.
At the time, Lilly had already managed to keep the documents hidden by settling out of court with about 8,000 Zyprexa victims in 2005 by paying close to $700 million, after only five plaintiffs had provided depositions and before any substantive depositions could be taken from any of the Lilly defendants.
And the first batch out of court settlements did nothing to deter the off-label sales of Zyprexa. According to Lilly's SEC filings, sales in the second quarter of 2006 totaled $1.12 billion, or a 2% increase over the second quarter of 2005.
In addition, Dr Egilman was aware that the company was getting ready to settle with about 18,000 more Zyprexa victims, and that the second round of settlements would guarantee that the secret documents would remain sealed.
And as a condition of settlement, the 28,000 plaintiffs had to sign agreements promising never to discuss the charges made against the company related to Zyprexa.
According to several plaintiffs who settled out of court, they we were not aware that there were documents that showed in many instances that Lilly knew full well that the injuries suffered could occur and had intentionally concealed the information from doctors and patients because it would have had a negative impact on Zyprexa sales.
In fact, these plaintiffs said they were never told that these secret documents even existed much less that by signing settlement agreements they would be allowing more patients to be injured or killed because the documents would remain sealed.
They also said that they were completely surprised to learn that their attorneys had access to documents that could have been presented to a jury to prove that the allegations in their lawsuits were true when the media began reporting the story in December 2006.
For instance, a November 12, 1999, letter from a Dr Albert Marrero, to Lilly's medical director, described the blood sugar problems occurring in patients. "We have had eight patients out of possibly thirty-five patients on Zyprexa show up with high blood sugars," he stated.
Dr Marrero also told Lilly: "Two patients had to be hospitalized due to out of control diabetes....We have certainly never seen this with Haldol, Navane, Risperdal and others to this extent," he wrote.
A November 1999 report showed that after examining 70 clinical trials, Lilly found that 16% of patients on Zyprexa for a year had gained over 66 pounds but instead of informing doctors of this information, the company used data from a smaller group of trials to say about 30% of patients gained only 22 pounds.
Another document showed that in 2000, after a group of diabetes doctors retained by Lilly substantiated the diabetes risk, a Lilly manager stated in an email, "unless we come clean on this, it could get much more serious than we might anticipate."
A email dated two years later in March 2002, shows that Lilly shot down a plan to provide doctors with information about diabetes, because it would draw too much attention the risk. "Although M.D.'s like objective, educational materials, having our reps provide some with diabetes would further build its association to Zyprexa," the email stated.
Although the documents clearly show that Lilly had knowledge of these life-threatening health risks in 1999, it did not add a warning about blood sugar levels and diabetes to the Zyprexa label until the FDA forced it to in the fall of 2003. In fact, Japan and the UK issued warnings about the increased risk of diabetes in 2002.
According to Ellen Liversridge, whose son took Zyprexa and gained 100 pounds before he fell into a coma and died of profound hyperglycemia in 2002, "both the FDA and Lilly fought putting a warning on the label, until articles on the front pages of the New York Times, Baltimore Sun, and Wall Street Journal so embarrassed the FDA that they finally gave in to adding the warnings."
But even then she says, the FDA required the same warning on the labels of all atypical drugs, "when Zyprexa was associated with a 37% higher increase in the risk of diabetes when compared to other medications."
However, the secret documents show that Lilly was hard at work behind the scenes to make sure that the new warnings would have minimal effects on Zyprexa sales. A July 7, 2003, memo titled, "Diabetes Update," described a plan to protect doctors who were afraid of being sued for prescribing Zyprexa after the news of the diabetes risk became public that would indemnify doctors who continued to prescribe drug
"We must embrace the fact that many physicians are curtailing their use of Zyprexa (particularly in the moderately-ill patient and in the maintenance phase)," the Update said,
"solely on the basis of personal fear (of being sued)."
"Indemnification represents the most meaningful demonstration of confidence in Zyprexa--both with our customers and with our employees," it stated.
The memo also discussed a plan to pay millions of dollars to the National Alliance on Mental Illness, the most notorious industry backed front group in the nation, to help downplay the news about the diabetes risk.
The public health crisis created by patients who developed diabetes as a result of using Zyprexa is real. A Medicaid fraud lawsuit filed against Lilly by the attorney general of Mississippi in July 2006, alleges that about 10% of patients who used Zyprexa in that state have developed insulin-dependent diabetes and some are children, the complaint says.
When forced to make a decision on whether to warn the public about Zyprexa or abide by a court order that could result in the death and injury of thousands upon thousands of more people, Dr Egilman obviously followed the natural instinct of any decent human being and gave up the documents.
Whether or not he actually realized what consequences he might face is anyone's guess, but he no doubt recognizes the consequences of crossing the drug giant today.
On September 7, 2007, Lilly issued a press release with the headline: "Egilman Admits Wrongdoing in Illegally Releasing Documents to New York Times and Resolves Case to Avoid Possible Civil and Criminal Sanctions".
The release said that Dr Egilman will pay $100,000, and in return, the company "agreed to forego seeking criminal and civil penalties against Dr. Egilman for his illegal activities."
Although it will be interesting to see how many "Good Samaritans" will stick their neck out for the common good after hearing about Dr Egilman's fate, it is apparently still easy to find doctors willing to prescribe Zyprexa off-label because SEC filings show Lilly earned $4.36 billion from the drug in 2006
With all that said, on September 6, 2007, it was certainly a Deja Vue moment when the judge in Mr Gottstein's latest case against forced drugging in Alaska, issued an order to have the court hearing and file closed, even though the client had elected to have it open.
A catalog of articles written by award winning investigative journalist, Evelyn Pringle.
Sunday, August 8, 2010
Attorney Subpoenas J&J AstraZeneca and Lilly for Hidden Antipsychotic Data - Part II
Evelyn Pringle September 10, 2007
Attorney Jim Gottstein is the director of the Law Project for Psychiatric Rights, a public interest law firm that has mounted a campaign against forced psychiatric drugging all over the country. He represents mostly indigent clients through his non-profit organization and is not involved in the lawsuits filed against the atypical makers by patients or their families.
In turning the secret Eli Lilly documents over to the press, Mr Gottstein's goal was the same as Dr David Egilman's, to alert the public about Lilly's off-label marketing schemes aimed at getting doctors to prescribe Zyprexa to more patients who were unaware of the serious health risks associated with the drug.
Zyprexa was approved only for the treatment of adults with schizophrenia in 1996, and it wasn't until several years later, that it was approved for short-term treatment of adults with manic episodes associated with bipolar disorder.
In a February 13, 2007, interview with the Anchorage Daily News, Mr Gottstein explained that the secret document showed the rate at which Zyprexa caused diabetes, massive weight gain and other metabolic problems and how Lilly trained sales staff to mislead doctors about the drug's association with diabetes and illegally promoted Zyprexa for off-label use with children and the elderly.
As the playing field stands today, the average American alone would be lucky to find any law firm financially strong enough to take a drug giant like Lilly with its billions of dollars of power and a well that will never run dry in large part because the illegal off-label marketing of Zyprexa is ongoing and continues to earn billions of dollars each year.
However, a small group of patient advocates that included some of the most well-known psychiatric drug experts, journalists, and attorneys in the US went head to head with Lilly in the public battle in a US District Court in New York that dragged out over 2 months to lift an injunction that barred the public disclosure of information about the serious adverse effects of Zyprexa that Lilly had successfully kept hidden under a court order until the documents were leaked to the press in December 2006.
Lilly filed the motion for the injunction in attempt to get the documents back under seal and succeeded in muzzling just about every expert in the US involved in the fight to dismantle the mass-drugging schemes put in place by the pharmaceutical industry over the past 10 years including Dr Peter Breggin, Dr Grace Jackson, Dr David Cohen, and Dr Stefan Kruszewski, as well as the award winning journalist, Robert Whitaker, who wrote "Mad in America," and revealed all the negative information that showed up in the clinical trials conducted on Zyprexa and the other atypicals.
The score looked bad for the home team early on when Lilly won the second round by getting the court to add the names of two of the world's most powerful patient advocacy groups to the injunction, along with their internet web sites and leaders, including Vera Sharav, director of the Alliance for Human Research Protection, and Judy Chamberlin and David Oaks from the international organization MindFreedom, a coalition of about 100 advocacy groups in 13 different countries.
At the time, Mr Oaks said, "This appears to be about Eli Lilly using its billions of dollars to try to intimidate grassroots critics."
The New York legal battle turned into an all out war when Ms Sharav and Dr Cohen brought in the high profile attorney, Alan Milstein, to file their own motion asking the judge to unseal the documents because they should have never been designated confidential to begin with.
"What is abundantly clear," Mr Milstein told the judge in a hearing, "is that they are not trade secrets."
"Lilly in no way fears dissemination of these documents to their competitors, to Merck or to Glaxo," he said.
"What Lilly wants to prevent, is the public at large, the consumers of its products, from seeing these documents and learning the truth about the product that Lilly produces and the way it markets it," Mr Milstein said in the hearing.
Alaskan Attorney, John McKay, stepped in to represent Mr Gottstien and his wife Terrie, and then attorney, Fred von Lohmann of the Electronic Frontier Foundation, widened the battlefield by filing a brief on behalf of John Doe, described as a citizen-journalist who wanted to publish the secret documents on web sites because they were "plainly related to a matter of overriding public concern."
California attorney, Ted Chabasinski, jumped in the ring on behalf of Robert Whitaker, Judi Chamberlin, and David Oaks. "While the injunction purports to be an attempt to recover the documents," he wrote in a letter to the judge, "it is clear that its real purpose is to intimidate Lilly's critics, and the court should refuse to cooperate with this."
Mr Chabasinski told the court that criminal charges should be filed against Lilly executives for illegally marketing Zyprexa for unapproved uses, with full knowledge that thousands of patients were being injured and killed. "If executives can go to prison for stealing their companies' money," he told the judge in a letter, "surely those who steal people's lives deserve at least the same fate."
Mr Chabasinski informed the court that the secret documents were evidence of Lilly executives' "criminal behavior" and their "willingness to kill people for profit." He also made it known that he was encouraging members of the public to contact state attorney generals and was directing private citizens to a list of current contact information for each state posted on the Mindfreedom web site.
And some citizens did just that. Richard Bleecker, whose nephew died unexpectedly of hyperglycemia due to Zyprexa, wrote to the New Jersey attorney general and stated: "In your capacity as New Jersey's Attorney General, I ask that you launch an investigation into Eli Lilly's violation of the public interest by its concealment of the risks of Zyprexa."
"Despite the FDA restrictions on use and warning labels," he wrote, "the drug continues to be vigorously promoted by Lilly and prescribed for patients in record numbers, including children."
He pointed that the state itself had an interest in the matter "since government programs like Medicare and Medicaid purchase over 70% of the Zyprexa sold in the USA, taxpayers in our State as well as across the nation are footing most of the bill."
"I appeal to you, to investigate Eli Lilly's willingness to see patients suffer and die to enhance its profits," Mr Bleeker wrote.
Over 10 states have now sued Lilly for Medicaid fraud over the off-label marketing of Zyprexa. And for good reason according to a report in the March 23, 2007, New York Times, that said Zyprexa costs more than $300 a month and is the single biggest drug expense for state Medicaid programs with spending of more than $1.3 billion in 2005.
During court hearings, several people restrained by the injunction testified about why the documents should be made public which resulted in media reports about what was in them before the legal battle even ended.
For instance, at a January 17, 2007, hearing, Mr Gottstein was asked, "at the time you subpoenaed Dr. Egilman, had you the impression that Eli Lilly had deliberately withheld from the public and from physicians adverse side effects of Zyprexa?"
And he answered: "Absolutely."
He was then asked whether he feared there would be thousands more cases of harm to people from Zyprexa, while Lilly was settling cases out of court, and Mr Gottstein said yes, and that he wanted the documents released "to protect people from this drug."
Mr Milstein told the judge that the documents were critically important to saving human lives and said, "this Court should in no way assist Lilly in keeping them from the public."
At the same hearing, Lilly attorneys asked Ms Sharav why she was interested in the documents and she said because they documented the fact that Lilly knew in 2000, that Zyprexa caused diabetes, "from a group of doctors that they hired who told them you have to come clean."
"And instead of warning doctors who are widely prescribing the drug, Eli Lilly set about in an aggressive marketing campaign to primary doctors," she testified.
Ms Sharav told the court, "This is a safety issue," and "to continue to conceal these facts" from the public "is not in the public interest."
She said, "this is about the worst that I have seen."
"It borders on indifference to human life," she told the judge. "Eli Lilly knew that Zyprexa causes hypoglycemia, diabetes, cardiovascular damage and they set about both to market it unlawfully for off label uses to primary care physicians."
She said Lilly taught primary care doctors to diagnose patients as bipolar if they experienced mania after taking antidepressants. "That is absolutely outrageous and that is one of the reasons that I felt that this should involve the Attorney General," she testified.
Mr Sharav also objected to the off-label sale of Zyprexa to kids. "Little children are being exposed to horrific diseases that end their lives shorter," she testified.
She said, "the reason the drug became a four and a half billion dollar seller in the United States is because they encouraged the prescription for children, for the elderly, for all sorts of reasons."
"I consider that a major crime," she told the judge and said she asked Mr Gottstein for 2 copies of the documents so that she could deliver one copy to the New York attorney general.
By the time of that hearing, Ms Sharav no doubt was aware that the crime was ongoing because in January 2006, USA Today reported that although the atypicals are not approved for any use with children, the prescription rate for children "is growing dramatically faster than the rate for adults," quoting Robert Epstein, chief medical officer for Medco Health Solutions, pharmacy benefit managers.
In addition, an assessment by Christoph Correll, of the Child and Adolescent Psychiatric Clinics of North America, showed Zyprexa to be the worst of the atypicals for kids and listed the side effects of diabetes and weight gain with the drug as "severe."
Technically, on February 13, 2007, Lilly scored a knock-out punch when the judge issued a permanent injunction prohibiting Mr Gottstein and Dr Egilman from further disseminating the documents and allowed Lilly to keep them sealed under a court order.
However, the judge also acknowledged in his written ruling that there was no way he could not enjoin the world by extending the injunction to the internet and by that time the worldwide web was flooded with all the damning information.
And Lilly would soon learn that the push to make the information public extended far beyond the courtroom. On February 23, 2007, a grass roots advocacy group issued a press release to rally support for Mr Gottstein for providing the documents to the media and to announce the "The Just Say "Know" to Prescription Drugs Campaign," with a goal of getting one million people reevaluate the prescription drugs they were taking.
"If there is a case that dramatically highlights the need to stop blindly taking prescriptions drugs, this is it," said Dr Greg Tefft, co-founder of the Campaign.
"We're talking 20 million people potentially at risk and more being added daily," he added.
The group set out to educate the public about off-label prescribing and what consumers must do to protect themselves against Zyprexa, or other drugs, when they are prescribed without warnings about side effects or unapproved uses.
"We are convinced that the way to solve this problem is to work the demand side of the market," Dr Tefft said. "We are going directly to consumers and encouraging them to know what they are taking."
Chairman of the Campaign, Dr Dominick Riccio, hosted a Zyprexa radio series and Dr Laurence Simon provided information to consumers about the drug and they set up an official web site for the Campaign is http://justsayknow.kpncradio.com
A month and a half later, on April 4, 2007, the ranking Republican on the Senate Committee on Finance, Senator Charles Grassley (R-Iowa), was knocking on Lilly's door with a letter to the CEO saying, "I have an obligation to ensure that the public's money is properly spent to provide safe and effective treatments to the vulnerable populations that are beneficiaries of the Medicare and Medicaid programs."
"I am aware of several pending products liability actions regarding Zyprexa," he said, "and questions have been raised regarding safety information and marketing practices relating to that drug."
Senator Grassley also wrote, "I understand that Eli Lilly produced certain documents in the course of these litigations that shed light on issues of interest to the Committee," referring to leaked documents and said, "please provide to the Committee all documents and materials, including, but not limited to, emails, letters, reports, and memoranda, that were made available ... pursuant to pretrial discovery in In re Zyprexa Prods. Liab. Litig."
And in the end, it could be said that injunction or no injunction, the small group of warriors led by Mr Gottstein and Dr Egilman, who bravely banded together against the billion dollar giant helped make Lilly's worst nightmare come true by fighting against the injunction and keeping the spotlight on the documents that the company fought so hard to keep hidden, not so much from the public, but from the stockholders.
According to legal experts, Lilly's desperate filing for the injunction had nothing to do with the lawsuits filed by private plaintiffs because that litigation was the least of its worries being the company was settling the cases for peanuts with plaintiffs signing confidentiality agreements that would shut them up for life.
However, following the public disclosure of proof that Lilly had engaged in a 10-year illegal off-label marketing scheme while concealing the adverse effects of Zyprexa, the company was hit with the big Kahoona, when 4 class action lawsuits were filed in April 2007 on behalf of shareholders, alleging the fraud by Lilly and its top executives had cost them more than $30 billion, and the evidenced cited to support the allegations was the information from the secret documents that resulted in the battle over the injunction.
It remains to be seen whether these shareholder lawsuits will do anything to stop the drugging of kids in the US because as it stands right now the mass drugging campaign appears to be unstoppable. On September 5, 2007, Rob Waters reported that the number of antipsychotic prescriptions for children doubled to 4.4 million between 2003 and 2006, citing data provided to Bloomberg News by Wolters Kluwer NV, a drug-tracking firm.
Mr Waters also reported that the growth was most dramatic in the youngest children with 20,280 prescriptions written for kids aged 4 and younger, a five-fold increase over 2003, and with 5- to 9-year-olds, prescriptions increased almost six-fold to 710,937 in 2006.
Attorney Jim Gottstein is the director of the Law Project for Psychiatric Rights, a public interest law firm that has mounted a campaign against forced psychiatric drugging all over the country. He represents mostly indigent clients through his non-profit organization and is not involved in the lawsuits filed against the atypical makers by patients or their families.
In turning the secret Eli Lilly documents over to the press, Mr Gottstein's goal was the same as Dr David Egilman's, to alert the public about Lilly's off-label marketing schemes aimed at getting doctors to prescribe Zyprexa to more patients who were unaware of the serious health risks associated with the drug.
Zyprexa was approved only for the treatment of adults with schizophrenia in 1996, and it wasn't until several years later, that it was approved for short-term treatment of adults with manic episodes associated with bipolar disorder.
In a February 13, 2007, interview with the Anchorage Daily News, Mr Gottstein explained that the secret document showed the rate at which Zyprexa caused diabetes, massive weight gain and other metabolic problems and how Lilly trained sales staff to mislead doctors about the drug's association with diabetes and illegally promoted Zyprexa for off-label use with children and the elderly.
As the playing field stands today, the average American alone would be lucky to find any law firm financially strong enough to take a drug giant like Lilly with its billions of dollars of power and a well that will never run dry in large part because the illegal off-label marketing of Zyprexa is ongoing and continues to earn billions of dollars each year.
However, a small group of patient advocates that included some of the most well-known psychiatric drug experts, journalists, and attorneys in the US went head to head with Lilly in the public battle in a US District Court in New York that dragged out over 2 months to lift an injunction that barred the public disclosure of information about the serious adverse effects of Zyprexa that Lilly had successfully kept hidden under a court order until the documents were leaked to the press in December 2006.
Lilly filed the motion for the injunction in attempt to get the documents back under seal and succeeded in muzzling just about every expert in the US involved in the fight to dismantle the mass-drugging schemes put in place by the pharmaceutical industry over the past 10 years including Dr Peter Breggin, Dr Grace Jackson, Dr David Cohen, and Dr Stefan Kruszewski, as well as the award winning journalist, Robert Whitaker, who wrote "Mad in America," and revealed all the negative information that showed up in the clinical trials conducted on Zyprexa and the other atypicals.
The score looked bad for the home team early on when Lilly won the second round by getting the court to add the names of two of the world's most powerful patient advocacy groups to the injunction, along with their internet web sites and leaders, including Vera Sharav, director of the Alliance for Human Research Protection, and Judy Chamberlin and David Oaks from the international organization MindFreedom, a coalition of about 100 advocacy groups in 13 different countries.
At the time, Mr Oaks said, "This appears to be about Eli Lilly using its billions of dollars to try to intimidate grassroots critics."
The New York legal battle turned into an all out war when Ms Sharav and Dr Cohen brought in the high profile attorney, Alan Milstein, to file their own motion asking the judge to unseal the documents because they should have never been designated confidential to begin with.
"What is abundantly clear," Mr Milstein told the judge in a hearing, "is that they are not trade secrets."
"Lilly in no way fears dissemination of these documents to their competitors, to Merck or to Glaxo," he said.
"What Lilly wants to prevent, is the public at large, the consumers of its products, from seeing these documents and learning the truth about the product that Lilly produces and the way it markets it," Mr Milstein said in the hearing.
Alaskan Attorney, John McKay, stepped in to represent Mr Gottstien and his wife Terrie, and then attorney, Fred von Lohmann of the Electronic Frontier Foundation, widened the battlefield by filing a brief on behalf of John Doe, described as a citizen-journalist who wanted to publish the secret documents on web sites because they were "plainly related to a matter of overriding public concern."
California attorney, Ted Chabasinski, jumped in the ring on behalf of Robert Whitaker, Judi Chamberlin, and David Oaks. "While the injunction purports to be an attempt to recover the documents," he wrote in a letter to the judge, "it is clear that its real purpose is to intimidate Lilly's critics, and the court should refuse to cooperate with this."
Mr Chabasinski told the court that criminal charges should be filed against Lilly executives for illegally marketing Zyprexa for unapproved uses, with full knowledge that thousands of patients were being injured and killed. "If executives can go to prison for stealing their companies' money," he told the judge in a letter, "surely those who steal people's lives deserve at least the same fate."
Mr Chabasinski informed the court that the secret documents were evidence of Lilly executives' "criminal behavior" and their "willingness to kill people for profit." He also made it known that he was encouraging members of the public to contact state attorney generals and was directing private citizens to a list of current contact information for each state posted on the Mindfreedom web site.
And some citizens did just that. Richard Bleecker, whose nephew died unexpectedly of hyperglycemia due to Zyprexa, wrote to the New Jersey attorney general and stated: "In your capacity as New Jersey's Attorney General, I ask that you launch an investigation into Eli Lilly's violation of the public interest by its concealment of the risks of Zyprexa."
"Despite the FDA restrictions on use and warning labels," he wrote, "the drug continues to be vigorously promoted by Lilly and prescribed for patients in record numbers, including children."
He pointed that the state itself had an interest in the matter "since government programs like Medicare and Medicaid purchase over 70% of the Zyprexa sold in the USA, taxpayers in our State as well as across the nation are footing most of the bill."
"I appeal to you, to investigate Eli Lilly's willingness to see patients suffer and die to enhance its profits," Mr Bleeker wrote.
Over 10 states have now sued Lilly for Medicaid fraud over the off-label marketing of Zyprexa. And for good reason according to a report in the March 23, 2007, New York Times, that said Zyprexa costs more than $300 a month and is the single biggest drug expense for state Medicaid programs with spending of more than $1.3 billion in 2005.
During court hearings, several people restrained by the injunction testified about why the documents should be made public which resulted in media reports about what was in them before the legal battle even ended.
For instance, at a January 17, 2007, hearing, Mr Gottstein was asked, "at the time you subpoenaed Dr. Egilman, had you the impression that Eli Lilly had deliberately withheld from the public and from physicians adverse side effects of Zyprexa?"
And he answered: "Absolutely."
He was then asked whether he feared there would be thousands more cases of harm to people from Zyprexa, while Lilly was settling cases out of court, and Mr Gottstein said yes, and that he wanted the documents released "to protect people from this drug."
Mr Milstein told the judge that the documents were critically important to saving human lives and said, "this Court should in no way assist Lilly in keeping them from the public."
At the same hearing, Lilly attorneys asked Ms Sharav why she was interested in the documents and she said because they documented the fact that Lilly knew in 2000, that Zyprexa caused diabetes, "from a group of doctors that they hired who told them you have to come clean."
"And instead of warning doctors who are widely prescribing the drug, Eli Lilly set about in an aggressive marketing campaign to primary doctors," she testified.
Ms Sharav told the court, "This is a safety issue," and "to continue to conceal these facts" from the public "is not in the public interest."
She said, "this is about the worst that I have seen."
"It borders on indifference to human life," she told the judge. "Eli Lilly knew that Zyprexa causes hypoglycemia, diabetes, cardiovascular damage and they set about both to market it unlawfully for off label uses to primary care physicians."
She said Lilly taught primary care doctors to diagnose patients as bipolar if they experienced mania after taking antidepressants. "That is absolutely outrageous and that is one of the reasons that I felt that this should involve the Attorney General," she testified.
Mr Sharav also objected to the off-label sale of Zyprexa to kids. "Little children are being exposed to horrific diseases that end their lives shorter," she testified.
She said, "the reason the drug became a four and a half billion dollar seller in the United States is because they encouraged the prescription for children, for the elderly, for all sorts of reasons."
"I consider that a major crime," she told the judge and said she asked Mr Gottstein for 2 copies of the documents so that she could deliver one copy to the New York attorney general.
By the time of that hearing, Ms Sharav no doubt was aware that the crime was ongoing because in January 2006, USA Today reported that although the atypicals are not approved for any use with children, the prescription rate for children "is growing dramatically faster than the rate for adults," quoting Robert Epstein, chief medical officer for Medco Health Solutions, pharmacy benefit managers.
In addition, an assessment by Christoph Correll, of the Child and Adolescent Psychiatric Clinics of North America, showed Zyprexa to be the worst of the atypicals for kids and listed the side effects of diabetes and weight gain with the drug as "severe."
Technically, on February 13, 2007, Lilly scored a knock-out punch when the judge issued a permanent injunction prohibiting Mr Gottstein and Dr Egilman from further disseminating the documents and allowed Lilly to keep them sealed under a court order.
However, the judge also acknowledged in his written ruling that there was no way he could not enjoin the world by extending the injunction to the internet and by that time the worldwide web was flooded with all the damning information.
And Lilly would soon learn that the push to make the information public extended far beyond the courtroom. On February 23, 2007, a grass roots advocacy group issued a press release to rally support for Mr Gottstein for providing the documents to the media and to announce the "The Just Say "Know" to Prescription Drugs Campaign," with a goal of getting one million people reevaluate the prescription drugs they were taking.
"If there is a case that dramatically highlights the need to stop blindly taking prescriptions drugs, this is it," said Dr Greg Tefft, co-founder of the Campaign.
"We're talking 20 million people potentially at risk and more being added daily," he added.
The group set out to educate the public about off-label prescribing and what consumers must do to protect themselves against Zyprexa, or other drugs, when they are prescribed without warnings about side effects or unapproved uses.
"We are convinced that the way to solve this problem is to work the demand side of the market," Dr Tefft said. "We are going directly to consumers and encouraging them to know what they are taking."
Chairman of the Campaign, Dr Dominick Riccio, hosted a Zyprexa radio series and Dr Laurence Simon provided information to consumers about the drug and they set up an official web site for the Campaign is http://justsayknow.kpncradio.com
A month and a half later, on April 4, 2007, the ranking Republican on the Senate Committee on Finance, Senator Charles Grassley (R-Iowa), was knocking on Lilly's door with a letter to the CEO saying, "I have an obligation to ensure that the public's money is properly spent to provide safe and effective treatments to the vulnerable populations that are beneficiaries of the Medicare and Medicaid programs."
"I am aware of several pending products liability actions regarding Zyprexa," he said, "and questions have been raised regarding safety information and marketing practices relating to that drug."
Senator Grassley also wrote, "I understand that Eli Lilly produced certain documents in the course of these litigations that shed light on issues of interest to the Committee," referring to leaked documents and said, "please provide to the Committee all documents and materials, including, but not limited to, emails, letters, reports, and memoranda, that were made available ... pursuant to pretrial discovery in In re Zyprexa Prods. Liab. Litig."
And in the end, it could be said that injunction or no injunction, the small group of warriors led by Mr Gottstein and Dr Egilman, who bravely banded together against the billion dollar giant helped make Lilly's worst nightmare come true by fighting against the injunction and keeping the spotlight on the documents that the company fought so hard to keep hidden, not so much from the public, but from the stockholders.
According to legal experts, Lilly's desperate filing for the injunction had nothing to do with the lawsuits filed by private plaintiffs because that litigation was the least of its worries being the company was settling the cases for peanuts with plaintiffs signing confidentiality agreements that would shut them up for life.
However, following the public disclosure of proof that Lilly had engaged in a 10-year illegal off-label marketing scheme while concealing the adverse effects of Zyprexa, the company was hit with the big Kahoona, when 4 class action lawsuits were filed in April 2007 on behalf of shareholders, alleging the fraud by Lilly and its top executives had cost them more than $30 billion, and the evidenced cited to support the allegations was the information from the secret documents that resulted in the battle over the injunction.
It remains to be seen whether these shareholder lawsuits will do anything to stop the drugging of kids in the US because as it stands right now the mass drugging campaign appears to be unstoppable. On September 5, 2007, Rob Waters reported that the number of antipsychotic prescriptions for children doubled to 4.4 million between 2003 and 2006, citing data provided to Bloomberg News by Wolters Kluwer NV, a drug-tracking firm.
Mr Waters also reported that the growth was most dramatic in the youngest children with 20,280 prescriptions written for kids aged 4 and younger, a five-fold increase over 2003, and with 5- to 9-year-olds, prescriptions increased almost six-fold to 710,937 in 2006.
Psychotropic Drug Makers Bankroll Prescribing Shrinks Part I
Evelyn Pringle August 30, 2007
On August 21, 2007, the Associated Press reported that drug companies spend a lot of money on the members of Minnesota advisory panels who help select the drugs which are to be used by patients covered by Medicaid.
The news agency's review of financial disclosure records in Minnesota found that a doctor and a pharmacist on the 8-member panel simultaneously received large checks from drug companies for speaking about their products.
According to the report, Minneapolis psychiatrist John Simon, appointed to the panel in 2004, earned $354,700 from drug makers that included Eli Lilly and AstraZeneca, from 2004 to 2006, in honoraria, speaker and consulting fees, as well as other payments ranging from $500 to $93,012.
The records also showed that Robert Straka, a University of Minnesota pharmacy professor, was paid $78,000 by drug companies while he served on the panel from 2000 to 2006. He told the Associated Press that he was paid for "educational talks" and that he routinely discloses his ties with drug companies and did so as a panel member, both verbally and in writing.
But according to information obtained with a public records request by the AP, there is no indication that Mr Straka made any such disclosures in meeting minutes dating back to February 2001, and other panel members and staff interviewed by the AP could not remember Mr Straka making any such disclosures either.
The Associated Press reported that roughly a third of the drugs on Minnesota's preferred drug list were sold by companies which paid Mr Simon or Mr Straka, but the news agency could not track any link between the payments and their votes because the minutes from the advisory panel meetings did not record how the 8 members voted.
The top-selling drugs prescribed to Minnesota Medicaid patients for the years 2000 through 2006 included the atypical antipsychotic drugs Zyprexa, marketed by Eli Lilly; Seroquel, sold by AstraZeneca; Risperdal, marketed by Johnson & Johnson subsidiary Janssen; Geodon, sold by Pfizer, and Abilify, from Bristol-Myers Squibb.
These drugs were originally FDA-approved for the limited use of treating adults with schizophrenia or the manic phase of bipolar disorder. However, the massive over-prescribing of this enormously expensive class of drugs for unapproved uses has caused many states to remove them from the Medicaid preferred drugs lists and requires doctors to obtain prior authorization before prescribing them to Medicaid patients.
In fact, roughly 10 states are now suing several atypical makers for Medicaid fraud to recoup the cost of purchasing the antipsychotics prescribed off-label to Medicaid patients and also to recover the money paid for medical care of the persons injured by the drugs.
The lawsuits allege that the drug makers illegally influenced doctors to prescribe the drugs off-label to patients of all ages, for conditions such as behavior and mood disorders, eating disorders, anxiety, post traumatic stress disorder, insomnia, PMS, dementia, and many other unapproved indications, and concealed the adverse effects associated with the drugs.
The atypical makers are also facing tens of thousands of lawsuits filed by patients, private insurance carriers and company shareholders for similar allegations.
According to Lilly's August 6, 2007, SEC filing, since August 2006, Lilly has received civil investigative demands or subpoenas from a number of states. "Most of these requests are now part of a multistate investigative effort being coordinated by an executive committee of attorneys general," the filing states.
"We are aware that approximately 30 states," Lilly wrote, "are participating in this joint effort, and it is possible that additional states will join the investigation."
The filing notes that the attorneys general are seeking a broad range of Zyprexa documents, "including documents relating to sales, marketing and promotional practices, and remuneration of health care providers."
Presumably, that would also include the "remuneration" of Minnesota shrinks like Dr Simon. According to the August 27, 2007, Pioneer Press, since 2002, Dr Simon has received more than $570,000 from six drug makers, with most of the money coming from Eli Lilly, "whose antipsychotic drug Zyprexa is the most costly each year for Minnesota's fee-for-service health program for the poor and disabled," the article states.
In fact, Lilly's disclosure records for 2004 show payments to Dr Simon totaling a whopping $91,854.95 in that one year, and he also received another couple grand from Seroquel maker AstraZeneca.
Dr Simon told the Pioneer Press that companies pay him to speak about their drugs at conferences and clinics or about the conditions that are treated with the drugs. "Most of the psychiatrists who are really good," he said, "have ties to industry."
Whether Dr Simon is a "really good" psychiatrist is certainly open to debate. In 1997, the state medical board made him complete a clinical training program and issued a report which said that Dr Simon, "frequently makes abrupt and drastic changes in type and dosage of medication which seem erratic, not well considered and poorly integrated with nonmedication strategies."
The board also noted that Dr Simon prescribed addictive drugs to addicts and failed to stop giving medicines to patients when they were suffering severe drug side effects. He said in an interview with the Times that the board's action was a learning experience and that drug makers continued to hire him to speak because he was respected by his peers.
For years, Dr Simon reportedly shared an office with another "really good" psychiatrist by the name of Dr Faruk Abuzzahab. On June 3, 2007, Gardiner Harris and Janet Roberts published a story in the New York Times with the headline: "After Sanctions, Doctors Get Drug Company Pay," and stated:
A decade ago, the Minnesota Board of Medical Practice accused Dr. Faruk Abuzzahab of a "reckless, if not willful, disregard" for the welfare of 46 patients, 5 of whom died in his care or shortly afterward. The board suspended his license for seven months and restricted it for two years after that.
Over the past 20 years, this "really good" psychiatrist has repeatedly prescribed narcotics and other controlled substances to addicts and prescribed narcotics to pregnant women, one of whom delivered a baby prematurely that died, the board found.
The Times reports that separately, in 1979 and 1984, the FDA concluded that Dr Abuzzahab had violated the protocols of every study that the agency audited and that he reported inaccurate data to drug makers.
The FDA said he routinely oversaw 4 to 8 trials at the same time, moved patients from one study to another, gave experimental drugs to patients at their first consultation and once hospitalized a patient for the sole purpose of enrolling him in a study.
As recently as June 2006, the medical board criticized Dr Abuzzahab once again for writing prescriptions for narcotics and this time to patients he knew were using false names, according to the Times.
All that said, Dr Abuzzahab told the Times that he has helped study many popular psychiatric drugs, including Lilly's Zyprexa and Prozac, Janssen's Risperdal, AstraZeneca's Seroquel, Glaxo's Paxil and Pfizer's Zoloft.
A review of the Minnesota disclosure records for 2004 show that the drug makers apparently thought it was beneficial to keep paying big bucks to Dr Abuzzahab. Glaxo paid him $1,000, Pfizer gave him $750, and Wyeth forked over $18,084, in that year alone.
In 2003, psychiatrist Dr Ronald Hardrict pleaded guilty to Medicaid fraud. But a little charge like fraud apparently did not effect this Minnesota psychiatrist's earning power either. The very next year, disclosure records for 2004 show Risperdal maker Janssen paid him $10,000; Seroquel maker AstraZeneca gave $1,250; Abbott Labs paid him over $7500; Glaxo paid $1,500, and Wyeth forked over $8,846.
In reviewing the Minnesota disclosure records for 2004, the name Dr Dean Knudson kept popping up. A September 2004 Newsletter from the Ada Canyon Medical Education Consortium listed Dr Knudson as an associate professor of psychiatry at the University of Minnesota Medical School.
He must be a "really good" psychiatrist, too, because in 2004 alone, Lilly paid him close to $37,000; he earned nearly $2,750 from Pfizer; Seroquel maker AstraZeneca paid him $6,700; Janssen forked over $3750; Wyeth paid him $11,632, and he received $2,082 from Abbott. Lilly's 2003 forms also show another $8,740 paid to Dr Knudson.
The newsletter showed that Dr Knudson was paid to give educational presentations on dementia. On October 18, 2005, the Associated Press reported a study that showed atypicals used to treat elderly patients with dementia raised their risk of death.
For the study, the researchers pooled the results of 15 studies on the atypicals Zyprexa, Risperdal, Seroquel and Abilify and among more than 5,000 dementia patients, those taking any of the four drugs faced a 54% increased risk of dying within 12 weeks of starting the drugs, compared to patients taking placebos.
Another name that jumps out in the 2004 disclosure records is Dr David Adson. According to the August 20, 2007, Pioneer Press, Dr Adson, of the University of Minnesota, also has a state advisory role as the clinical leader of a program funded by Lilly and provided free of charge to Minnesota, which notifies doctors when their prescriptions for psychiatric drugs are out of line with clinical standards.
Although the program is funded by Lilly, it is supposedly run by an independent company called Comprehensive NeuroScience, Inc. All totaled, 20 states have contracts with CNS to identify doctors "who are prescribing psychiatric drugs outside of recommended guidelines for safety and effectiveness," according to the Press.
Critics say the program is actually a scam set up with state policy makers to make sure the expensive psychiatric drugs remain on the Medicaid covered drug lists instead of being placed on the lists that require prior authorization.
Ben Hansen, a member of the Michigan Department of Community Health Recipient Rights Advisory Committee, has been investigating the atypical makers' involvement in the Medicaid programs in Michigan and other states and says that none of the states with CNS contracts require prior authorization for the atypical drugs.
Mr Hansen published some of the results of his investigation in the Spring 2007 Newsletter of the International Center for the Study of Psychiatry and Psychology. By using the FOIA, Mr Hansen says he has obtained nearly a thousand pages of documents which show that Medicaid is being "milked like a huge cash cow."
According to Allen Jones, a former Medicaid fraud investigator, the long list of corporate sponsors for CNS includes: AstraZeneca, Janssen, Bristol-Myers, Pfizer, Lilly and Glaxo.
Back in 2002, Mr Jones found that Janssen was using CNS to funnel payments to state officials who controlled the Medicaid preferred drug lists in Pennsylvania to ensure that Risperdal would be on the list.
For his part, the leader of the Minnesota CNS program, Dr Adson, was paid $5,200 by AstraZeneca, Glaxo shows $331,947 going to him, and Pfizer gave him $1,000, in 2004 alone.
Also, in 2006, Dr Adson received $83,325 from AstraZeneca and roughly $6,100 from Bristol-Myers, according to a compilation of disclosure forms by the Pioneer Press and the watchdog group Public Citizen.
On August 21, 2007, the Associated Press reported that drug companies spend a lot of money on the members of Minnesota advisory panels who help select the drugs which are to be used by patients covered by Medicaid.
The news agency's review of financial disclosure records in Minnesota found that a doctor and a pharmacist on the 8-member panel simultaneously received large checks from drug companies for speaking about their products.
According to the report, Minneapolis psychiatrist John Simon, appointed to the panel in 2004, earned $354,700 from drug makers that included Eli Lilly and AstraZeneca, from 2004 to 2006, in honoraria, speaker and consulting fees, as well as other payments ranging from $500 to $93,012.
The records also showed that Robert Straka, a University of Minnesota pharmacy professor, was paid $78,000 by drug companies while he served on the panel from 2000 to 2006. He told the Associated Press that he was paid for "educational talks" and that he routinely discloses his ties with drug companies and did so as a panel member, both verbally and in writing.
But according to information obtained with a public records request by the AP, there is no indication that Mr Straka made any such disclosures in meeting minutes dating back to February 2001, and other panel members and staff interviewed by the AP could not remember Mr Straka making any such disclosures either.
The Associated Press reported that roughly a third of the drugs on Minnesota's preferred drug list were sold by companies which paid Mr Simon or Mr Straka, but the news agency could not track any link between the payments and their votes because the minutes from the advisory panel meetings did not record how the 8 members voted.
The top-selling drugs prescribed to Minnesota Medicaid patients for the years 2000 through 2006 included the atypical antipsychotic drugs Zyprexa, marketed by Eli Lilly; Seroquel, sold by AstraZeneca; Risperdal, marketed by Johnson & Johnson subsidiary Janssen; Geodon, sold by Pfizer, and Abilify, from Bristol-Myers Squibb.
These drugs were originally FDA-approved for the limited use of treating adults with schizophrenia or the manic phase of bipolar disorder. However, the massive over-prescribing of this enormously expensive class of drugs for unapproved uses has caused many states to remove them from the Medicaid preferred drugs lists and requires doctors to obtain prior authorization before prescribing them to Medicaid patients.
In fact, roughly 10 states are now suing several atypical makers for Medicaid fraud to recoup the cost of purchasing the antipsychotics prescribed off-label to Medicaid patients and also to recover the money paid for medical care of the persons injured by the drugs.
The lawsuits allege that the drug makers illegally influenced doctors to prescribe the drugs off-label to patients of all ages, for conditions such as behavior and mood disorders, eating disorders, anxiety, post traumatic stress disorder, insomnia, PMS, dementia, and many other unapproved indications, and concealed the adverse effects associated with the drugs.
The atypical makers are also facing tens of thousands of lawsuits filed by patients, private insurance carriers and company shareholders for similar allegations.
According to Lilly's August 6, 2007, SEC filing, since August 2006, Lilly has received civil investigative demands or subpoenas from a number of states. "Most of these requests are now part of a multistate investigative effort being coordinated by an executive committee of attorneys general," the filing states.
"We are aware that approximately 30 states," Lilly wrote, "are participating in this joint effort, and it is possible that additional states will join the investigation."
The filing notes that the attorneys general are seeking a broad range of Zyprexa documents, "including documents relating to sales, marketing and promotional practices, and remuneration of health care providers."
Presumably, that would also include the "remuneration" of Minnesota shrinks like Dr Simon. According to the August 27, 2007, Pioneer Press, since 2002, Dr Simon has received more than $570,000 from six drug makers, with most of the money coming from Eli Lilly, "whose antipsychotic drug Zyprexa is the most costly each year for Minnesota's fee-for-service health program for the poor and disabled," the article states.
In fact, Lilly's disclosure records for 2004 show payments to Dr Simon totaling a whopping $91,854.95 in that one year, and he also received another couple grand from Seroquel maker AstraZeneca.
Dr Simon told the Pioneer Press that companies pay him to speak about their drugs at conferences and clinics or about the conditions that are treated with the drugs. "Most of the psychiatrists who are really good," he said, "have ties to industry."
Whether Dr Simon is a "really good" psychiatrist is certainly open to debate. In 1997, the state medical board made him complete a clinical training program and issued a report which said that Dr Simon, "frequently makes abrupt and drastic changes in type and dosage of medication which seem erratic, not well considered and poorly integrated with nonmedication strategies."
The board also noted that Dr Simon prescribed addictive drugs to addicts and failed to stop giving medicines to patients when they were suffering severe drug side effects. He said in an interview with the Times that the board's action was a learning experience and that drug makers continued to hire him to speak because he was respected by his peers.
For years, Dr Simon reportedly shared an office with another "really good" psychiatrist by the name of Dr Faruk Abuzzahab. On June 3, 2007, Gardiner Harris and Janet Roberts published a story in the New York Times with the headline: "After Sanctions, Doctors Get Drug Company Pay," and stated:
A decade ago, the Minnesota Board of Medical Practice accused Dr. Faruk Abuzzahab of a "reckless, if not willful, disregard" for the welfare of 46 patients, 5 of whom died in his care or shortly afterward. The board suspended his license for seven months and restricted it for two years after that.
Over the past 20 years, this "really good" psychiatrist has repeatedly prescribed narcotics and other controlled substances to addicts and prescribed narcotics to pregnant women, one of whom delivered a baby prematurely that died, the board found.
The Times reports that separately, in 1979 and 1984, the FDA concluded that Dr Abuzzahab had violated the protocols of every study that the agency audited and that he reported inaccurate data to drug makers.
The FDA said he routinely oversaw 4 to 8 trials at the same time, moved patients from one study to another, gave experimental drugs to patients at their first consultation and once hospitalized a patient for the sole purpose of enrolling him in a study.
As recently as June 2006, the medical board criticized Dr Abuzzahab once again for writing prescriptions for narcotics and this time to patients he knew were using false names, according to the Times.
All that said, Dr Abuzzahab told the Times that he has helped study many popular psychiatric drugs, including Lilly's Zyprexa and Prozac, Janssen's Risperdal, AstraZeneca's Seroquel, Glaxo's Paxil and Pfizer's Zoloft.
A review of the Minnesota disclosure records for 2004 show that the drug makers apparently thought it was beneficial to keep paying big bucks to Dr Abuzzahab. Glaxo paid him $1,000, Pfizer gave him $750, and Wyeth forked over $18,084, in that year alone.
In 2003, psychiatrist Dr Ronald Hardrict pleaded guilty to Medicaid fraud. But a little charge like fraud apparently did not effect this Minnesota psychiatrist's earning power either. The very next year, disclosure records for 2004 show Risperdal maker Janssen paid him $10,000; Seroquel maker AstraZeneca gave $1,250; Abbott Labs paid him over $7500; Glaxo paid $1,500, and Wyeth forked over $8,846.
In reviewing the Minnesota disclosure records for 2004, the name Dr Dean Knudson kept popping up. A September 2004 Newsletter from the Ada Canyon Medical Education Consortium listed Dr Knudson as an associate professor of psychiatry at the University of Minnesota Medical School.
He must be a "really good" psychiatrist, too, because in 2004 alone, Lilly paid him close to $37,000; he earned nearly $2,750 from Pfizer; Seroquel maker AstraZeneca paid him $6,700; Janssen forked over $3750; Wyeth paid him $11,632, and he received $2,082 from Abbott. Lilly's 2003 forms also show another $8,740 paid to Dr Knudson.
The newsletter showed that Dr Knudson was paid to give educational presentations on dementia. On October 18, 2005, the Associated Press reported a study that showed atypicals used to treat elderly patients with dementia raised their risk of death.
For the study, the researchers pooled the results of 15 studies on the atypicals Zyprexa, Risperdal, Seroquel and Abilify and among more than 5,000 dementia patients, those taking any of the four drugs faced a 54% increased risk of dying within 12 weeks of starting the drugs, compared to patients taking placebos.
Another name that jumps out in the 2004 disclosure records is Dr David Adson. According to the August 20, 2007, Pioneer Press, Dr Adson, of the University of Minnesota, also has a state advisory role as the clinical leader of a program funded by Lilly and provided free of charge to Minnesota, which notifies doctors when their prescriptions for psychiatric drugs are out of line with clinical standards.
Although the program is funded by Lilly, it is supposedly run by an independent company called Comprehensive NeuroScience, Inc. All totaled, 20 states have contracts with CNS to identify doctors "who are prescribing psychiatric drugs outside of recommended guidelines for safety and effectiveness," according to the Press.
Critics say the program is actually a scam set up with state policy makers to make sure the expensive psychiatric drugs remain on the Medicaid covered drug lists instead of being placed on the lists that require prior authorization.
Ben Hansen, a member of the Michigan Department of Community Health Recipient Rights Advisory Committee, has been investigating the atypical makers' involvement in the Medicaid programs in Michigan and other states and says that none of the states with CNS contracts require prior authorization for the atypical drugs.
Mr Hansen published some of the results of his investigation in the Spring 2007 Newsletter of the International Center for the Study of Psychiatry and Psychology. By using the FOIA, Mr Hansen says he has obtained nearly a thousand pages of documents which show that Medicaid is being "milked like a huge cash cow."
According to Allen Jones, a former Medicaid fraud investigator, the long list of corporate sponsors for CNS includes: AstraZeneca, Janssen, Bristol-Myers, Pfizer, Lilly and Glaxo.
Back in 2002, Mr Jones found that Janssen was using CNS to funnel payments to state officials who controlled the Medicaid preferred drug lists in Pennsylvania to ensure that Risperdal would be on the list.
For his part, the leader of the Minnesota CNS program, Dr Adson, was paid $5,200 by AstraZeneca, Glaxo shows $331,947 going to him, and Pfizer gave him $1,000, in 2004 alone.
Also, in 2006, Dr Adson received $83,325 from AstraZeneca and roughly $6,100 from Bristol-Myers, according to a compilation of disclosure forms by the Pioneer Press and the watchdog group Public Citizen.
Psychotropic Drug Makers Bankroll Prescribing Shrinks Part II
Evelyn Pringle September 2, 2007
Influence peddling in the field of psychiatry is out of control. An analysis of Minnesota disclosure records by the Pioneer Press and the consumer watchdog group Public Citizen shows that, between 2002 and 2006, 187 Minnesota doctors received payments from drug companies worth a grand total of $7.38 million.
No other field of medicine even comes close to that amount. The next highest specialty was neurology, with 99 doctors receiving $2.89 million, according to the analysis.
In psychiatry, drug makers underwrite decision makers at every level of care, according to a May 10, 2007, report by Gardiner Harris in the New York Times. "They pay doctors who prescribe and recommend drugs, teach about the underlying diseases, perform studies and write guidelines that other doctors often feel bound to follow," Mr Harris states.
He determined that, between 2000 and 2005, payments to Minnesota psychiatrists increased more than six-fold. The Times also analyzed Minnesota Medicaid records, and the report provides details on how the financial relationships between doctors and drug makers have played a major role in the growing use of atypical antipsychotics with children.
The drugs include Zyprexa, marketed by Eli Lilly; Seroquel, by AstraZeneca; Risperdal, marketed by Johnson & Johnson subsidiary Janssen; Geodon, sold by Pfizer, and Abilify, from Bristol-Myers Squibb.
The drugs are the most powerful psychiatric drugs on the market and were FDA-approved only to treat adults with schizophrenia or adults in the manic phase of bipolar disorder.
Over the past three years, every atypical maker has come under fire for influencing doctors to prescribe the drugs off-label to children for uses never approved by the FDA, and they are all currently involved in litigation related to the illegal promotion and sales of the drugs.
A study at Columbia University on the use of antipsychotics with children found that only a small percentage of the kids on the drugs had psychotic disorders and that, most of the time, the drugs were prescribed to treat mood disorders, depression, anxiety and ADHD.
Mr Harris reports that the Minnesota psychiatrists who received the most money from the drug's makers tended to prescribe them to kids the most often. On average, psychiatrists who received at least $5,000 between 2000 to 2005 appeared to have written 3 times as many prescriptions for kids as psychiatrists who received less or no money, the Times notes.
The rising Medicaid costs for atypicals also coincides with the rising payments to doctors. For instance, Minnesota Medicaid spent roughly $521,000 in 2000 on antipsychotics for children; but in 2005, the cost was more than $7 million, or a 14-fold increase.
In June 2007, Vermont officials revealed that disclosure records in that state showed payments to psychiatrists had more than doubled in one year, from an average of $20,835 in 2005, to an average $45,692 in 2005. There, too, antipsychotics were among the highest Medicaid drug expense.
The drug makers have shrinks in their pockets all over the country. However, only 3 states, Minnesota, Vermont and Maine, have laws that require companies to disclose their payments.
The media's recent reporting that members of a Minnesota advisory panel who decide which drugs will be covered by the state's Medicaid program are on the take, adds a new chapter to an old book. This same scam has been used in states all over the country since the late 1990's, and if not for two relentless fraud investigators from Pennsylvania, the fact that the formulary committees are bought and paid for by the pharmaceutical industry might have remained a secret for all time.
The fact that drug makers were bribing state policy makers and members of advisory panels with the ultimate goal of capturing the lucrative Medicaid customer base to increase the sale of psychiatric drugs was first discovered several years ago by Allen Jones, while he was a federal fraud investigator in the Pennsylvania Office of Inspector General Bureau of Special Investigations, and Dr Stefan Kruszewski, a pediatric psychiatrist by trade, who was hired by the Pennsylvania Department of Public Welfare to review the quality of care provided to persons covered by state programs.
According to Mr Jones, "the pharmaceutical industry has systematically infiltrated the mental health service delivery system of this nation."
"The situation uncovered in Minnesota," he says, "will be exposed in every state that demonstrates the political will to force transparency through full disclosure of industry payments to decision makers."
"Thinly veiled bribery of public officials by the pharmaceutical industry is a pervasive and deeply rooted problem," he warns.
During his investigation in Pennsylvania, Mr Jones found a drug money trail to key policy officials who controlled the Medicaid preferred drug list in that state, which eventually led him to Texas and an elaborate scheme that involved influential psychiatrists, including many who served as professors at Texas universities, and state policy officials who developed the preferred drug list known as the "Texas Medication Algorithm Project (TMAP)".
Mr Jones calls the Texas panel the "most transparent example" of industry influence, because all of the project directors had financial ties to the drug makers. It was put into effect, he says, by buying off doctors who were considered "opinion leaders" in the psychiatric field, along with state policy makers in positions of authority with control over the preferred drug lists.
For instance, Dr John Rush, from the University of Texas Southwestern Medical Center, served as the TMAP Project Co-Director with Dr Steven Shon, the Medical Director of the Texas Department of State Health Services.
Mr Jones determined that Dr Rush had received grants, research funding and served as a consultant and speaker for atypical makers Bristol-Myers, Janssen, Eli Lilly and Pfizer.
The director for the schizophrenia module was Dr Alexander Miller, of the University of Texas Health Science Center at San Antonio, who also served as a consultant, advisory board member and speaker for AstraZeneca, Bristol-Myers, Lilly, Janssen and Pfizer.
The director of the bipolar disorder module was Dr Patricia Suppes, from the University of Texas Southwestern Medical Center in Dallas, who also received grants and research funding and served as a consultant for AstraZeneca, Bristol-Myers, Janssen, Lilly and Pfizer.
Other University of Texas professors who participated in the development of TMAP included psychiatrist Dr Graham Emslie, who has received grants and research support and served as a consultant and member of speakers' bureaus for atypical makers Bristol-Myers, Lilly and Pfizer.
Another professor, Dr Karen Dineen Wagner, was a member of the speakers' bureaus for Janssen, Lilly and Pfizer, and a member of a scientific advisory board for Lilly, Janssen and Pfizer and received research funding from the same 3 atypical makers and Bristol-Myers.
Once the formulary was in place in Texas, the drug makers paid Dr Shon to travel around the country to convince policy makers in other states to use the TMAP model for their Medicaid approved list. Pennsylvania adopted the program and called it PennMap.
Mr Jones found that Janssen paid for Dr Shon to fly to Pennsylvania two times, and a document he obtained shows that the grant covering Dr Shon's travel expenses was "to expand atypical usage."
The New York Times reported that some payments were made through patient advocacy groups instead of directly to state officials. In 2002, Janssen gave the Olympia, WA, chapter of the National Alliance for the Mentally Ill a grant of $15,000 to fly Dr Shon and other Texas officials to speak to state legislators about the formulary, the Times found.
While reviewing the medical care provided to patients under state care in the summer of 2002, Dr Kruszewski immediately recognized that a mass drugging-for-profit scheme involving Medicaid patients, especially children, was taking place in Pennsylvania, and that several patients had died.
In one case, where the child fortunately survived, Dr Kruszewski found that the girl had been placed on 11 psychiatric drugs at the same time, including 5 antipsychotics, without ever being diagnosed with a psychiatric disorder. She exhibited impulsive behaviors and was mentally disabled, but there was nothing in the records to justify the use of all these drugs, he says.
According Dr Kruszewski, the atypicals are associated with an increased the risk of obesity which can lead to diabetes type II, hypertension, heart attacks and stroke. The weight of the girl who was on 11 drugs had ballooned from 106 pounds to 194, Dr Kruszewski found.
In reviewing patient records, he found a state-wide pattern where patients who were not mentally ill were placed on cocktails of 3 or more expensive psychiatric drugs at the same time and kept on the cocktails indefinitely and if patients experienced side effects from the original medications, more drugs were added to the mix.
The sheer greed evidenced by the mass drugging of patients on Medicaid all over the US, similar to that discovered by Dr Kruszewski in Pennsylvania, has forced state Medicaid programs to either put a stop to the drug maker's encouragement of the rampant prescribing of atypicals or go broke.
For instance, Texas Medicaid was charged nearly $15 million for antipsychotics for foster children in 2004, according to the December 2006 Special Report, "Foster Children - Texas Health Care Claims Study." In fact, Texas spent more money on antipsychotics for foster kids than any other class of drugs, and the report said, Zyprexa, Seroquel and Risperdal typically cost an average of $229 per prescription.
The report also pointed out that the drugs were not approved for children, and listed the health risks associated with the atypicals and stated, in part:
"These very powerful and expensive medications were prescribed despite a lack of studies demonstrating their safety and efficacy in children. There are questions regarding the long-term safety of these medications; documented serious side-effects include menstrual irregularities, gynecomastia, galactorrhea, possible pituitary tumors, hyperglycemia, type 2 diabetes and liver function abnormalities."
In a May 10, 2006 Press Release, Comptroller Carole Keeton Strayhorn said she was "particularly concerned" about the use and side effects of the atypical antipsychotic drugs.
"A clear pattern of overmedication and potential misdiagnosis of foster children is evident," she said and the "potential for Medicaid fraud and the possibility of long-term health problems in these children is alarming."
A USA TODAY study of FDA data from 2000 to 2004 found 45 pediatric deaths in which atypicals were the primary suspect, with at least six related to diabetes and other causes ranged from heart and pulmonary problems to Zyprexa, choking and liver failure.
A 15-year-old boy died of an overdose, an 8-year-old boy died of cardiac arrest, a 13-year-old girl experienced diabetic ketoacidosis, a deficiency of insulin, and the youngest death was a 4-year-old boy whose symptoms suggested diabetes complications, who was also taking 10 other drugs.
A July 29, 2007, report by Robert Farley in the St Petersburg Times revealed that in the last 7 years, the cost to Florida tax payers for atypicals prescribed to children jumped nearly 500%, from $4.7 million to $27.5 million, and on average in 2006, it cost the state nearly $1,800 for each child on atypicals.
Mr Farley reported that last year, more than 18,000 kids on Medicaid were prescribed antipsychotics including 1,100 under the age of 6 and some as young as 3, even though guidelines from the Florida Agency for Health Care Administration say children younger than 6 should generally not be given psychotropic drugs and they should "only be considered under the most extraordinary of circumstances."
According to Mr Jones, these new "miracle" drugs have proven to be no better than generics, and, "it is a statistical certainty that many lives have been lost and many others irreparably damaged."
In September 2005, the New England Journal of Medicine, reported that although Zyprexa was the most expensive and most prescribed antipsychotic, it was the only atypical that worked slightly better than the 40-year-old generic drug, perphenazine, but the NEJM also noted that Zyprexa had more side effects. The cost for a 3 month supply of Zyprexa in September, 2005 at drugstore.com, was $1,500, while a 3 month supply of perphenazine was only $135.
And the atypical drugging for profit scheme is not limited to the Medicaid population. An analysis revealed in March 2006 by investment firm CIBC World Markets showed that in the previous 12 months, the top 20 drugs in managed care spending included Zyprexa with $2.6 billion, Seroquel at $2.5 billion, and Risperdal was $2.2 billion.
The corrupt psychiatrists in Minnesota and other states might want to think about what is happening to "professionals" who were involved in similar behavior in Pennsylvania and Texas.
In Pennsylvania, the state Ethics Commission determined that Pfizer operated its own "Advisory Boards," comprised exclusively of formulary committee chairmen from various states who received honorariums and all-expense-paid trips from Pfizer at the same time they were evaluating Pfizer drugs for use in state mental health systems.
The Commission determined that Steven Fiorello, Director of the Pharmacy Services in the Office of Mental Health and Substance Abuse Services in Pennsylvania, and Chairman of the Formulary Committee, had used his office to obtain private pecuniary benefits for his participation in Pfizer's advisory board meetings in New York when he received honoraria for his participation in the meetings, as well as for his presentations at conferences in Orlando, Florida and Dublin, Ireland.
Mr Jones found that Mr Fiorello traveled to Pfizer's world headquarters in Manhattan 3 times to participate in advisory board meetings, with all expenses paid for by Pfizer, including lodging at Manhattan's Millennium Hotel and he was paid an honorarium of $1,000 for attending each meeting.
The Commission also found a number of additional violations, including Mr Fiorello's receipt of honoraria from other companies for whom he made presentations in connection with his public employment, and ordered Mr Fiorello to make restitution of $27,268.50 and referred the case to the Pennsylvania Attorney General's Public Corruption Unit.
On November 21, 2006, Mr Fiorello was charged with two counts of conflicts of interest, one count of accepting honoraria and one count of failing to disclose income on annual Statements of Financial Interests. In a press release, Pennsylvania's Attorney General stated: "As part of his responsibilities, Fiorello served on a committee that decided which drugs would be used for mental health treatment in all state hospitals - decisions which guided more than $9 million in annual drug purchases by the Commonwealth."
He also noted that, "while Fiorello was helping to guide the purchase of various drugs by the Department of Public Welfare, he was also paid more than $12,000 by drug companies for appearances, speeches and presentations, as well as service on a drug company advisory board."
Down in Texas, Dr Shon was fired last fall after the state's attorney general found that Janssen had improperly influenced him to list Risperdal on the state formulary. An October 9, 2006, letter to Dr Shon from Dr Charles Bell, acting commissioner of the Texas Department of State Health Services, obtained by the Austin American-Statesman states: "It is my determination that your services are no longer required by the Department."
"I am, therefore, terminating you as the Medical Director for Behavioral Health effective immediately," Dr Bell wrote.
In addition, Texas is now closely monitoring the prescribing of psychiatric drugs to Medicaid patients, and several psychiatrists have been ordered to reimburse the state for the cost of the drugs they prescribed to foster children.
Texas and Pennsylvania have also recently filed Medicaid fraud lawsuits against the makers of Zyprexa, Risperdal and Seroquel, seeking to recoup the cost of the drugs prescribed to Medicaid patients, as well as the medical care for persons injured by the drugs.
Influence peddling in the field of psychiatry is out of control. An analysis of Minnesota disclosure records by the Pioneer Press and the consumer watchdog group Public Citizen shows that, between 2002 and 2006, 187 Minnesota doctors received payments from drug companies worth a grand total of $7.38 million.
No other field of medicine even comes close to that amount. The next highest specialty was neurology, with 99 doctors receiving $2.89 million, according to the analysis.
In psychiatry, drug makers underwrite decision makers at every level of care, according to a May 10, 2007, report by Gardiner Harris in the New York Times. "They pay doctors who prescribe and recommend drugs, teach about the underlying diseases, perform studies and write guidelines that other doctors often feel bound to follow," Mr Harris states.
He determined that, between 2000 and 2005, payments to Minnesota psychiatrists increased more than six-fold. The Times also analyzed Minnesota Medicaid records, and the report provides details on how the financial relationships between doctors and drug makers have played a major role in the growing use of atypical antipsychotics with children.
The drugs include Zyprexa, marketed by Eli Lilly; Seroquel, by AstraZeneca; Risperdal, marketed by Johnson & Johnson subsidiary Janssen; Geodon, sold by Pfizer, and Abilify, from Bristol-Myers Squibb.
The drugs are the most powerful psychiatric drugs on the market and were FDA-approved only to treat adults with schizophrenia or adults in the manic phase of bipolar disorder.
Over the past three years, every atypical maker has come under fire for influencing doctors to prescribe the drugs off-label to children for uses never approved by the FDA, and they are all currently involved in litigation related to the illegal promotion and sales of the drugs.
A study at Columbia University on the use of antipsychotics with children found that only a small percentage of the kids on the drugs had psychotic disorders and that, most of the time, the drugs were prescribed to treat mood disorders, depression, anxiety and ADHD.
Mr Harris reports that the Minnesota psychiatrists who received the most money from the drug's makers tended to prescribe them to kids the most often. On average, psychiatrists who received at least $5,000 between 2000 to 2005 appeared to have written 3 times as many prescriptions for kids as psychiatrists who received less or no money, the Times notes.
The rising Medicaid costs for atypicals also coincides with the rising payments to doctors. For instance, Minnesota Medicaid spent roughly $521,000 in 2000 on antipsychotics for children; but in 2005, the cost was more than $7 million, or a 14-fold increase.
In June 2007, Vermont officials revealed that disclosure records in that state showed payments to psychiatrists had more than doubled in one year, from an average of $20,835 in 2005, to an average $45,692 in 2005. There, too, antipsychotics were among the highest Medicaid drug expense.
The drug makers have shrinks in their pockets all over the country. However, only 3 states, Minnesota, Vermont and Maine, have laws that require companies to disclose their payments.
The media's recent reporting that members of a Minnesota advisory panel who decide which drugs will be covered by the state's Medicaid program are on the take, adds a new chapter to an old book. This same scam has been used in states all over the country since the late 1990's, and if not for two relentless fraud investigators from Pennsylvania, the fact that the formulary committees are bought and paid for by the pharmaceutical industry might have remained a secret for all time.
The fact that drug makers were bribing state policy makers and members of advisory panels with the ultimate goal of capturing the lucrative Medicaid customer base to increase the sale of psychiatric drugs was first discovered several years ago by Allen Jones, while he was a federal fraud investigator in the Pennsylvania Office of Inspector General Bureau of Special Investigations, and Dr Stefan Kruszewski, a pediatric psychiatrist by trade, who was hired by the Pennsylvania Department of Public Welfare to review the quality of care provided to persons covered by state programs.
According to Mr Jones, "the pharmaceutical industry has systematically infiltrated the mental health service delivery system of this nation."
"The situation uncovered in Minnesota," he says, "will be exposed in every state that demonstrates the political will to force transparency through full disclosure of industry payments to decision makers."
"Thinly veiled bribery of public officials by the pharmaceutical industry is a pervasive and deeply rooted problem," he warns.
During his investigation in Pennsylvania, Mr Jones found a drug money trail to key policy officials who controlled the Medicaid preferred drug list in that state, which eventually led him to Texas and an elaborate scheme that involved influential psychiatrists, including many who served as professors at Texas universities, and state policy officials who developed the preferred drug list known as the "Texas Medication Algorithm Project (TMAP)".
Mr Jones calls the Texas panel the "most transparent example" of industry influence, because all of the project directors had financial ties to the drug makers. It was put into effect, he says, by buying off doctors who were considered "opinion leaders" in the psychiatric field, along with state policy makers in positions of authority with control over the preferred drug lists.
For instance, Dr John Rush, from the University of Texas Southwestern Medical Center, served as the TMAP Project Co-Director with Dr Steven Shon, the Medical Director of the Texas Department of State Health Services.
Mr Jones determined that Dr Rush had received grants, research funding and served as a consultant and speaker for atypical makers Bristol-Myers, Janssen, Eli Lilly and Pfizer.
The director for the schizophrenia module was Dr Alexander Miller, of the University of Texas Health Science Center at San Antonio, who also served as a consultant, advisory board member and speaker for AstraZeneca, Bristol-Myers, Lilly, Janssen and Pfizer.
The director of the bipolar disorder module was Dr Patricia Suppes, from the University of Texas Southwestern Medical Center in Dallas, who also received grants and research funding and served as a consultant for AstraZeneca, Bristol-Myers, Janssen, Lilly and Pfizer.
Other University of Texas professors who participated in the development of TMAP included psychiatrist Dr Graham Emslie, who has received grants and research support and served as a consultant and member of speakers' bureaus for atypical makers Bristol-Myers, Lilly and Pfizer.
Another professor, Dr Karen Dineen Wagner, was a member of the speakers' bureaus for Janssen, Lilly and Pfizer, and a member of a scientific advisory board for Lilly, Janssen and Pfizer and received research funding from the same 3 atypical makers and Bristol-Myers.
Once the formulary was in place in Texas, the drug makers paid Dr Shon to travel around the country to convince policy makers in other states to use the TMAP model for their Medicaid approved list. Pennsylvania adopted the program and called it PennMap.
Mr Jones found that Janssen paid for Dr Shon to fly to Pennsylvania two times, and a document he obtained shows that the grant covering Dr Shon's travel expenses was "to expand atypical usage."
The New York Times reported that some payments were made through patient advocacy groups instead of directly to state officials. In 2002, Janssen gave the Olympia, WA, chapter of the National Alliance for the Mentally Ill a grant of $15,000 to fly Dr Shon and other Texas officials to speak to state legislators about the formulary, the Times found.
While reviewing the medical care provided to patients under state care in the summer of 2002, Dr Kruszewski immediately recognized that a mass drugging-for-profit scheme involving Medicaid patients, especially children, was taking place in Pennsylvania, and that several patients had died.
In one case, where the child fortunately survived, Dr Kruszewski found that the girl had been placed on 11 psychiatric drugs at the same time, including 5 antipsychotics, without ever being diagnosed with a psychiatric disorder. She exhibited impulsive behaviors and was mentally disabled, but there was nothing in the records to justify the use of all these drugs, he says.
According Dr Kruszewski, the atypicals are associated with an increased the risk of obesity which can lead to diabetes type II, hypertension, heart attacks and stroke. The weight of the girl who was on 11 drugs had ballooned from 106 pounds to 194, Dr Kruszewski found.
In reviewing patient records, he found a state-wide pattern where patients who were not mentally ill were placed on cocktails of 3 or more expensive psychiatric drugs at the same time and kept on the cocktails indefinitely and if patients experienced side effects from the original medications, more drugs were added to the mix.
The sheer greed evidenced by the mass drugging of patients on Medicaid all over the US, similar to that discovered by Dr Kruszewski in Pennsylvania, has forced state Medicaid programs to either put a stop to the drug maker's encouragement of the rampant prescribing of atypicals or go broke.
For instance, Texas Medicaid was charged nearly $15 million for antipsychotics for foster children in 2004, according to the December 2006 Special Report, "Foster Children - Texas Health Care Claims Study." In fact, Texas spent more money on antipsychotics for foster kids than any other class of drugs, and the report said, Zyprexa, Seroquel and Risperdal typically cost an average of $229 per prescription.
The report also pointed out that the drugs were not approved for children, and listed the health risks associated with the atypicals and stated, in part:
"These very powerful and expensive medications were prescribed despite a lack of studies demonstrating their safety and efficacy in children. There are questions regarding the long-term safety of these medications; documented serious side-effects include menstrual irregularities, gynecomastia, galactorrhea, possible pituitary tumors, hyperglycemia, type 2 diabetes and liver function abnormalities."
In a May 10, 2006 Press Release, Comptroller Carole Keeton Strayhorn said she was "particularly concerned" about the use and side effects of the atypical antipsychotic drugs.
"A clear pattern of overmedication and potential misdiagnosis of foster children is evident," she said and the "potential for Medicaid fraud and the possibility of long-term health problems in these children is alarming."
A USA TODAY study of FDA data from 2000 to 2004 found 45 pediatric deaths in which atypicals were the primary suspect, with at least six related to diabetes and other causes ranged from heart and pulmonary problems to Zyprexa, choking and liver failure.
A 15-year-old boy died of an overdose, an 8-year-old boy died of cardiac arrest, a 13-year-old girl experienced diabetic ketoacidosis, a deficiency of insulin, and the youngest death was a 4-year-old boy whose symptoms suggested diabetes complications, who was also taking 10 other drugs.
A July 29, 2007, report by Robert Farley in the St Petersburg Times revealed that in the last 7 years, the cost to Florida tax payers for atypicals prescribed to children jumped nearly 500%, from $4.7 million to $27.5 million, and on average in 2006, it cost the state nearly $1,800 for each child on atypicals.
Mr Farley reported that last year, more than 18,000 kids on Medicaid were prescribed antipsychotics including 1,100 under the age of 6 and some as young as 3, even though guidelines from the Florida Agency for Health Care Administration say children younger than 6 should generally not be given psychotropic drugs and they should "only be considered under the most extraordinary of circumstances."
According to Mr Jones, these new "miracle" drugs have proven to be no better than generics, and, "it is a statistical certainty that many lives have been lost and many others irreparably damaged."
In September 2005, the New England Journal of Medicine, reported that although Zyprexa was the most expensive and most prescribed antipsychotic, it was the only atypical that worked slightly better than the 40-year-old generic drug, perphenazine, but the NEJM also noted that Zyprexa had more side effects. The cost for a 3 month supply of Zyprexa in September, 2005 at drugstore.com, was $1,500, while a 3 month supply of perphenazine was only $135.
And the atypical drugging for profit scheme is not limited to the Medicaid population. An analysis revealed in March 2006 by investment firm CIBC World Markets showed that in the previous 12 months, the top 20 drugs in managed care spending included Zyprexa with $2.6 billion, Seroquel at $2.5 billion, and Risperdal was $2.2 billion.
The corrupt psychiatrists in Minnesota and other states might want to think about what is happening to "professionals" who were involved in similar behavior in Pennsylvania and Texas.
In Pennsylvania, the state Ethics Commission determined that Pfizer operated its own "Advisory Boards," comprised exclusively of formulary committee chairmen from various states who received honorariums and all-expense-paid trips from Pfizer at the same time they were evaluating Pfizer drugs for use in state mental health systems.
The Commission determined that Steven Fiorello, Director of the Pharmacy Services in the Office of Mental Health and Substance Abuse Services in Pennsylvania, and Chairman of the Formulary Committee, had used his office to obtain private pecuniary benefits for his participation in Pfizer's advisory board meetings in New York when he received honoraria for his participation in the meetings, as well as for his presentations at conferences in Orlando, Florida and Dublin, Ireland.
Mr Jones found that Mr Fiorello traveled to Pfizer's world headquarters in Manhattan 3 times to participate in advisory board meetings, with all expenses paid for by Pfizer, including lodging at Manhattan's Millennium Hotel and he was paid an honorarium of $1,000 for attending each meeting.
The Commission also found a number of additional violations, including Mr Fiorello's receipt of honoraria from other companies for whom he made presentations in connection with his public employment, and ordered Mr Fiorello to make restitution of $27,268.50 and referred the case to the Pennsylvania Attorney General's Public Corruption Unit.
On November 21, 2006, Mr Fiorello was charged with two counts of conflicts of interest, one count of accepting honoraria and one count of failing to disclose income on annual Statements of Financial Interests. In a press release, Pennsylvania's Attorney General stated: "As part of his responsibilities, Fiorello served on a committee that decided which drugs would be used for mental health treatment in all state hospitals - decisions which guided more than $9 million in annual drug purchases by the Commonwealth."
He also noted that, "while Fiorello was helping to guide the purchase of various drugs by the Department of Public Welfare, he was also paid more than $12,000 by drug companies for appearances, speeches and presentations, as well as service on a drug company advisory board."
Down in Texas, Dr Shon was fired last fall after the state's attorney general found that Janssen had improperly influenced him to list Risperdal on the state formulary. An October 9, 2006, letter to Dr Shon from Dr Charles Bell, acting commissioner of the Texas Department of State Health Services, obtained by the Austin American-Statesman states: "It is my determination that your services are no longer required by the Department."
"I am, therefore, terminating you as the Medical Director for Behavioral Health effective immediately," Dr Bell wrote.
In addition, Texas is now closely monitoring the prescribing of psychiatric drugs to Medicaid patients, and several psychiatrists have been ordered to reimburse the state for the cost of the drugs they prescribed to foster children.
Texas and Pennsylvania have also recently filed Medicaid fraud lawsuits against the makers of Zyprexa, Risperdal and Seroquel, seeking to recoup the cost of the drugs prescribed to Medicaid patients, as well as the medical care for persons injured by the drugs.
American Kids Being Drugged To Death
Evelyn Pringle August 22, 2007
As result of the marketing power the pharmaceutical industry obtained by spending tens of billions of dollars to gain influence over politicians in power, the FDA and the medical profession, American kids are being pumped full of the most powerful and dangerous psychiatric medications on the market, in drug cocktails that are literally killing them.
Neurologist Dr Fred Baughman, author of "The ADHD Fraud," calls the leadership of the psycho-pharm-government cartel (FDA, NIMH, White House New Freedom Commission on Mental Health) the biggest, most evil drug cartel in history. "At least the pusher of 'crack' on inner city streets does not come in a white coat," he says.
According Dr Baughman, kids have become "for-profit receptacles" for psychiatric drugs which will forever alter their brains and bodies. And its happening all across America he says, not by thousands but by tens of thousands.
Experts say the drugging regime usually begins by doctors convincing parents that their children have attention deficit disorder, and the medications prescribed are the exact same drugs that street addicts call "speed." They include the amphetamines Adderall, Dexedrine, and methylphenidates such as Ritalin and Concerta.
FDA records show that, between 1999 and 2003, seventy-eight million prescriptions were written for ADHD drugs for children ranging in age from one to 18. A review of adverse events posted on the FDA web site reveals that, between January 2000 and June 30, 2005, there were nearly 1,000 reports of psychosis or mania possibly linked to ADHD drugs, with psychosis characterized by the inability to distinguish real and imaginary events.
"The most important finding of this review is that signs of psychosis or mania, particularly hallucinations, can occur in patients with no identifiable risk factors, at usual doses of any of the drugs used to treat ADHD," according to a March 3, 2006, memo penned by two members of the agency's ADHD psychiatric review team.
FDA records also show reports of 25 deaths in children and adults between 1999 and 2003, and 54 cases of serious cardiovascular problems, including stokes, heart attacks, hypertension, palpitations and arrhythmia. But according to Dr Baughman, in addition to the deaths cited by the FDA, the MedWatch database also contains 186 more deaths of persons using ADHD drugs for the period between 1990 and 2000.
Dr Grace Jackson, author of "Rethinking Psychiatric Drugs: A Guide for Informed Consent," says that "whether by ignorance or design, the FDA remains oblivious to the evidence-based limitations of ADHD drugs."
She notes that at least 40% of children fail to respond or tolerate stimulant therapy, "and about twice as many respond at least as well to non-pharmacological interventions."
"The link between stimulants, cardiovascular disease, and death," Dr Jackson reports, "is well documented but doctors and government regulators have refused to acknowledge the dangers associated with the drugs."
The long-term outcomes for kids on ADHD drugs, she says, show diminishing effects over time, including "artificial behavioral improvements" which end when the medication is withdrawn.
Because stimulant drugs cause insomnia, sleeping pills are now being fed to children to counteract the insomnia side effect. Medco Health Solutions, a managed-care firm, found an 85% increase in the use of sleeping pills among children between 2002 and 2004.
One of the world's leading authorities on psychiatric drugs, Dr Peter Breggin, founder of the International Center for the Study of Psychiatry and Psychology and the journal Ethical Human Sciences and Services, warns that all ADHD drugs can cause "a continuum of stimulation, which includes agitation and irritability, anger, hostility, disinhibition, hypomania and mania."
The activation syndrome, he says, was observed decades ago with the amphetamines like Adderall and Dexedrine, and methylphenidates such as Ritalin and Concerta.
As an unrecognized side effect to most doctors, the syndrome more often than not results feeding the kids more drugs. As a child's emotional control breaks down due to the stimulant effects, Dr Breggin says, mood stabilizers such as antiseizure medications and antipsychotics may be added to the mix. "Eventually," he states, "these kids end up on four or five psychiatric drugs all at once and toddlers are even being diagnosed with bipolar disorder."
The new generation of "atypical" antipsychotics, originally approved only to treat adults with schizophrenia and bipolar disorder, which include Zyprexa (Eli Lilly), Risperdal (Johnson & Johnson), Seroquel (AstraZeneca), Abilify (Bristol-Myers Squibb), Clozaril (Novartis) and Geodon (Pfizer), were not approved for any condition in children, but studies of Medicaid records and HMO databases found an alarming increase in the use of these drugs by kids, particularly for behavioral disorders such as ADHD, according to the spring 2006 issue of the Journal of Ambulatory Pediatrics.
Researchers led by Dr William Cooper at Vanderbilt University analyzed data on health care services rendered in the US and found that between 1995 and 2002, there were 5,762,193 outpatient visits where children between the ages of 2 and 18 were prescribed an antipsychotic.
The researchers explained that there had been no increase in mental disorders and noted that, "schizophrenia and psychosis accounted for only 13.5% of the total antipsychotic visits during the study period, so this diagnosis alone could not explain the increase."
A USA TODAY analysis of the FDA's adverse event reporting system between 2000 and 2004 found at least 45 deaths of kids where the "primary suspect" was an atypical and more than 1,300 reports of other serious side effects.
Dr Breggin has served as an expert witness in several cases that resulted in favorable verdicts for the plaintiffs in which Risperdal caused a condition known as tardive dyskinesia in children, when it was prescribed in attempt to control behaviors that were in fact caused by ADHD drugs.
He explains that tardive dyskinesia is a neurological movement disorder that is often mistaken for a mental illness because the symptoms are so "strange" and "bizarre." The abnormal movements, he says, can affect any muscle group in the body and impair the ability to speak, walk, breathe and swallow.
According to Dr Breggin, this serious disorder occurs at a cumulative rate of between 4% and 7% in otherwise healthy patients taking antipsychotics each year and after only a few years, 20% or more of patients will be afflicted.
The drug makers have apparently found ways to influence the prescribing habits of Canadian doctors, because the new antipsychotics are now being doled out in record numbers to Canadian children for behavior and mood problems, with a significant proportion for children under nine, according to new research from Canada.
On June 18, 2007, Sharon Kirkey of CanWest News reported that ninety-four per cent of 176 child psychiatrists in Canada surveyed are prescribing the antipsychotics for a variety of disorders and symptoms, including anxiety, attention-deficit hyperactivity disorder and "poor frustration tolerance," citing a study in the Canadian Journal of Psychiatry
Risperdal was the most commonly prescribed, followed by Zyprexa and Seroquel. The report said that a "surprising" number of the prescriptions were for the very young, with 12% written for children aged eight or under, including three-year-olds, and noted that none of the drugs has been officially approved for use in children in Canada.
Lilly, J&J and AstraZeneca are currently named as defendants in Medicaid fraud lawsuits related to the illegal off-label marketing of Zyprexa, Risperdal and Seroquel, filed to recover money paid for patients' use the drugs, as well as the costs of medical care for patients injured by them.
In addition, investigations in several states have recently started looking into the behind-the-scenes financial relationships between the drug makers and some of the doctors who have been heavily involved in promoting the prescribing of the drugs for off-label uses.
As result of the marketing power the pharmaceutical industry obtained by spending tens of billions of dollars to gain influence over politicians in power, the FDA and the medical profession, American kids are being pumped full of the most powerful and dangerous psychiatric medications on the market, in drug cocktails that are literally killing them.
Neurologist Dr Fred Baughman, author of "The ADHD Fraud," calls the leadership of the psycho-pharm-government cartel (FDA, NIMH, White House New Freedom Commission on Mental Health) the biggest, most evil drug cartel in history. "At least the pusher of 'crack' on inner city streets does not come in a white coat," he says.
According Dr Baughman, kids have become "for-profit receptacles" for psychiatric drugs which will forever alter their brains and bodies. And its happening all across America he says, not by thousands but by tens of thousands.
Experts say the drugging regime usually begins by doctors convincing parents that their children have attention deficit disorder, and the medications prescribed are the exact same drugs that street addicts call "speed." They include the amphetamines Adderall, Dexedrine, and methylphenidates such as Ritalin and Concerta.
FDA records show that, between 1999 and 2003, seventy-eight million prescriptions were written for ADHD drugs for children ranging in age from one to 18. A review of adverse events posted on the FDA web site reveals that, between January 2000 and June 30, 2005, there were nearly 1,000 reports of psychosis or mania possibly linked to ADHD drugs, with psychosis characterized by the inability to distinguish real and imaginary events.
"The most important finding of this review is that signs of psychosis or mania, particularly hallucinations, can occur in patients with no identifiable risk factors, at usual doses of any of the drugs used to treat ADHD," according to a March 3, 2006, memo penned by two members of the agency's ADHD psychiatric review team.
FDA records also show reports of 25 deaths in children and adults between 1999 and 2003, and 54 cases of serious cardiovascular problems, including stokes, heart attacks, hypertension, palpitations and arrhythmia. But according to Dr Baughman, in addition to the deaths cited by the FDA, the MedWatch database also contains 186 more deaths of persons using ADHD drugs for the period between 1990 and 2000.
Dr Grace Jackson, author of "Rethinking Psychiatric Drugs: A Guide for Informed Consent," says that "whether by ignorance or design, the FDA remains oblivious to the evidence-based limitations of ADHD drugs."
She notes that at least 40% of children fail to respond or tolerate stimulant therapy, "and about twice as many respond at least as well to non-pharmacological interventions."
"The link between stimulants, cardiovascular disease, and death," Dr Jackson reports, "is well documented but doctors and government regulators have refused to acknowledge the dangers associated with the drugs."
The long-term outcomes for kids on ADHD drugs, she says, show diminishing effects over time, including "artificial behavioral improvements" which end when the medication is withdrawn.
Because stimulant drugs cause insomnia, sleeping pills are now being fed to children to counteract the insomnia side effect. Medco Health Solutions, a managed-care firm, found an 85% increase in the use of sleeping pills among children between 2002 and 2004.
One of the world's leading authorities on psychiatric drugs, Dr Peter Breggin, founder of the International Center for the Study of Psychiatry and Psychology and the journal Ethical Human Sciences and Services, warns that all ADHD drugs can cause "a continuum of stimulation, which includes agitation and irritability, anger, hostility, disinhibition, hypomania and mania."
The activation syndrome, he says, was observed decades ago with the amphetamines like Adderall and Dexedrine, and methylphenidates such as Ritalin and Concerta.
As an unrecognized side effect to most doctors, the syndrome more often than not results feeding the kids more drugs. As a child's emotional control breaks down due to the stimulant effects, Dr Breggin says, mood stabilizers such as antiseizure medications and antipsychotics may be added to the mix. "Eventually," he states, "these kids end up on four or five psychiatric drugs all at once and toddlers are even being diagnosed with bipolar disorder."
The new generation of "atypical" antipsychotics, originally approved only to treat adults with schizophrenia and bipolar disorder, which include Zyprexa (Eli Lilly), Risperdal (Johnson & Johnson), Seroquel (AstraZeneca), Abilify (Bristol-Myers Squibb), Clozaril (Novartis) and Geodon (Pfizer), were not approved for any condition in children, but studies of Medicaid records and HMO databases found an alarming increase in the use of these drugs by kids, particularly for behavioral disorders such as ADHD, according to the spring 2006 issue of the Journal of Ambulatory Pediatrics.
Researchers led by Dr William Cooper at Vanderbilt University analyzed data on health care services rendered in the US and found that between 1995 and 2002, there were 5,762,193 outpatient visits where children between the ages of 2 and 18 were prescribed an antipsychotic.
The researchers explained that there had been no increase in mental disorders and noted that, "schizophrenia and psychosis accounted for only 13.5% of the total antipsychotic visits during the study period, so this diagnosis alone could not explain the increase."
A USA TODAY analysis of the FDA's adverse event reporting system between 2000 and 2004 found at least 45 deaths of kids where the "primary suspect" was an atypical and more than 1,300 reports of other serious side effects.
Dr Breggin has served as an expert witness in several cases that resulted in favorable verdicts for the plaintiffs in which Risperdal caused a condition known as tardive dyskinesia in children, when it was prescribed in attempt to control behaviors that were in fact caused by ADHD drugs.
He explains that tardive dyskinesia is a neurological movement disorder that is often mistaken for a mental illness because the symptoms are so "strange" and "bizarre." The abnormal movements, he says, can affect any muscle group in the body and impair the ability to speak, walk, breathe and swallow.
According to Dr Breggin, this serious disorder occurs at a cumulative rate of between 4% and 7% in otherwise healthy patients taking antipsychotics each year and after only a few years, 20% or more of patients will be afflicted.
The drug makers have apparently found ways to influence the prescribing habits of Canadian doctors, because the new antipsychotics are now being doled out in record numbers to Canadian children for behavior and mood problems, with a significant proportion for children under nine, according to new research from Canada.
On June 18, 2007, Sharon Kirkey of CanWest News reported that ninety-four per cent of 176 child psychiatrists in Canada surveyed are prescribing the antipsychotics for a variety of disorders and symptoms, including anxiety, attention-deficit hyperactivity disorder and "poor frustration tolerance," citing a study in the Canadian Journal of Psychiatry
Risperdal was the most commonly prescribed, followed by Zyprexa and Seroquel. The report said that a "surprising" number of the prescriptions were for the very young, with 12% written for children aged eight or under, including three-year-olds, and noted that none of the drugs has been officially approved for use in children in Canada.
Lilly, J&J and AstraZeneca are currently named as defendants in Medicaid fraud lawsuits related to the illegal off-label marketing of Zyprexa, Risperdal and Seroquel, filed to recover money paid for patients' use the drugs, as well as the costs of medical care for patients injured by them.
In addition, investigations in several states have recently started looking into the behind-the-scenes financial relationships between the drug makers and some of the doctors who have been heavily involved in promoting the prescribing of the drugs for off-label uses.
SSRI-Induced Akathisia's Link To Suicide and Violence
Evelyn Pringle August 18, 2007
Medical experts have long known that the side effect associated with the class of antidepressants known as the selective serotonin reuptake inhibitors most likely to drive people to suicide or violence against others is "akathisia".
Akathisia is but one in a long list of side effects that SSRI makers were able to keep hidden, as they settled thousands of lawsuits out of court, by obtaining court orders to seal documents produced in litigation. For instance, a 1984 Eli Lilly document showed akathisia occurred in at least 1% of patients long before Prozac was approved.
In a paper entitled, "Suicides and Homicides in Patients Taking Paxil, Prozac, and Zoloft: Why They Keep Happening - And Why They Will Continue," Dr Jay Cohen points out that, as soon SSRI's arrived on the market in the late 1980s, reports of sudden, unexpected suicides and homicides by patients taking the drugs began to come in.
The DSM-IV acknowledges the association of akathisia with suicidality and states: "Akathisia may be associated with dysphoria, irritability, aggression, or suicide attempts."
According to Dr Cohen, SSRI's can create a combination of side effects that reduce impulse control and cause severe agitation or restlessness that may become intolerable. He says, impulsive behavior coupled with impaired cognitive functioning can be dangerous.
A 1998 article on akathisia associated with Prozac and its link to suicidal ideation in the Journal of Psychopharmacology, by Roger Lane, who was working for Pfizer at the time, states in part:
"It may be less of a question of patients experiencing fluoxetine-induced suicidal ideation than patients feeling that 'death is a welcome result' when the acutely discomforting symptoms of akathisia are experienced on top of already distressing disorders.
"Hamilton and Opler (1992) stated that the term 'suicidal ideation' to describe the apparent suicidality associated with akathisia was misleading, as the 'suicidal ideation' reported in patients receiving fluoxetine was a reaction to the side-effect of akathisia (i.e., unbearable discomfort and restlessness) and not true suicidal ideation as is typically described by depressed patients experiencing suicidal ideation."
Dr Joseph Glenmullen, author of "Prozac Backlash" and "The Antidepressant Solution," obtained a Lilly document dated November 13, 1990, from Claude Bouchy, a Lilly employee in Germany, to three executives at Lilly's Indianapolis headquarters, complaining about directions to change the identification of events as they are reported to doctors from "suicide attempt" to "overdose" and "suicidal ideation" to "depression".
"I do not think I could explain to the BGA, to a judge, to a reporter or even to my family," Mr Bouchy wrote, "why we would do this especially on the sensitive issue of suicide and suicide ideation."
Dr Glenmullen says akathisia makes people profoundly agitated, uncomfortable in their own skin and impulsive. It erodes judgment and can lower their threshold to become violent toward themselves or others, he states.
Dr Martin Teicher, an associate professor at Harvard Medical School and McLean Hospital researcher at the time, co-authored a paper with psychiatrist and psychopharmacologist Jonathan Cole on the link between Prozac and suicide back in 1990, which found that 3.5% of patients on Prozac either attempted or committed suicide due to severe agitation from akathisia.
In the paper, the authors discussed 6 cases of patients who became intensely preoccupied with suicide after taking Prozac. Dr Cole said, in an affidavit submitted in litigation on April 20, 2000, "Our purpose in writing this article was to alert the profession to an alarming, probable drug side effect which we had observed."
"There was a very clear association," he said, "not merely temporal, between the ingestion of Prozac and the patients' suicidality."
"I have also seen patients and reviewed cases," Dr Cole stated, "where an SSRI unmistakably precipitated a driven preoccupation with suicide."
"The SSRI drugs, as a class," he advised, "clearly have the potential to cause, and in reasonable medical probability or certainty do cause, akathisia in some patients."
"Although in 1997," Dr Cole notes, "practicing physicians undoubtedly varied in their level of sophistication and knowledge about the phenomenon, the potential to cause akathisia and its potential, in turn, to trigger suicidal behavior."
Additional evidence showing Lilly knew about the akathisia-induced suicide surfaced in an application for a patent for a second-generation Prozac pill which claimed that the new-and-improved Prozac would decrease the side effects of, "inner restlessness (akathisia), suicidal thoughts and self-mutilation."
Besides the concealment of this adverse effect by the drug companies, another major problem in getting the word out, according to Vince Boehm, who tracks all studies and research published on SSRI's, is that the FDA refuses to fully acknowledge the role of drug-induced akathisia in what he refers to as "this hideous equation."
"Akathisia is up to 6 times more likely to trigger a suicide," he states, "than any form of depression caused by life's circumstances alone."
"The minds inner turmoil is so intense that a person will do anything to escape it," he says.
"The Brits, the Aussies, Canada, and the European Union," he points out, "have all gone on record recognizing this phenomenon for all age groups."
Judging by internal FDA documents which have surfaced in litigation, Mr Boehm appears to be correct. For instance, in a September 11, 1990, memo, FDA scientist Dr David Graham found that Lilly's data on Prozac was insufficient to prove the drug was safe, stating: "Because of apparent large-scale underreporting, the firm's analysis cannot be considered as proving that fluoxetine and violent behavior are unrelated."
A more recent study in the September 2006 journal Public Library of Science (PLoS) has further verified the warnings made by many other experts, when it reported that, in addition to self-harm, SSRI's cause some patients to become violent and homicidal.
Dr David Healy, described as "one of the three most eminent academic clinical psychiatrists in the UK," professor David Menkes, from Cardiff University in Britain, and Andrew Herxheimer, from the Cochrane Centre, did the study to determine the risk of violent behavior in people taking SSRI's.
As part of their investigation, the researchers reviewed all available clinical data on SSRI's and summarized a series of "medico-legal" court cases involving patients who had became violent on SSRI's.
One case discussed dated back to 2001, when Dr Healy testified at a wrongful death trial in Wyoming, after a 60-year-old man on Paxil shot and killed his wife, daughter and infant granddaughter before turning the gun on himself in 1998.
At trial, the jury returned a verdict for the man's son-in-law after Dr Healy presented the jury with a summary of an unpublished company study that found incidents of serious aggression in 80 patients on Paxil, including 25 that involved homicide, and proved that the drug maker knew about the violence and suicide risks before the 1998 shootings.
Dr Healy points out a rechallenge study by Rothschild and Locke in McLean Hospital where the authors found Prozac-induced emergent suicidality associated with akathisia in several patients. In order to test whether suicidality was coincidental or associated with Prozac, they withdrew Prozac, then re-administered it, and in all three cases, the patients experienced the exact same effect. "All three patients developed severe akathisia during treatment with fluoxetine and stated that the development of the akathisia made them feel suicidal and that it had precipitated their prior suicide attempts."
However, even more alarming, one set of patients who became suicidal on Prozac were described as follows: "[n]one had a history of significant suicidal behavior; all described their distress as an intense and novel somatic-emotional state; all reported an urge to pace that paralleled the intensity of the distress; all experienced suicidal thoughts at the peak of their restless agitation; and all experienced a remission of their agitation, restlessness, pacing urge, and suicidality after the fluoxetine was discontinued."
Medical experts have long known that the side effect associated with the class of antidepressants known as the selective serotonin reuptake inhibitors most likely to drive people to suicide or violence against others is "akathisia".
Akathisia is but one in a long list of side effects that SSRI makers were able to keep hidden, as they settled thousands of lawsuits out of court, by obtaining court orders to seal documents produced in litigation. For instance, a 1984 Eli Lilly document showed akathisia occurred in at least 1% of patients long before Prozac was approved.
In a paper entitled, "Suicides and Homicides in Patients Taking Paxil, Prozac, and Zoloft: Why They Keep Happening - And Why They Will Continue," Dr Jay Cohen points out that, as soon SSRI's arrived on the market in the late 1980s, reports of sudden, unexpected suicides and homicides by patients taking the drugs began to come in.
The DSM-IV acknowledges the association of akathisia with suicidality and states: "Akathisia may be associated with dysphoria, irritability, aggression, or suicide attempts."
According to Dr Cohen, SSRI's can create a combination of side effects that reduce impulse control and cause severe agitation or restlessness that may become intolerable. He says, impulsive behavior coupled with impaired cognitive functioning can be dangerous.
A 1998 article on akathisia associated with Prozac and its link to suicidal ideation in the Journal of Psychopharmacology, by Roger Lane, who was working for Pfizer at the time, states in part:
"It may be less of a question of patients experiencing fluoxetine-induced suicidal ideation than patients feeling that 'death is a welcome result' when the acutely discomforting symptoms of akathisia are experienced on top of already distressing disorders.
"Hamilton and Opler (1992) stated that the term 'suicidal ideation' to describe the apparent suicidality associated with akathisia was misleading, as the 'suicidal ideation' reported in patients receiving fluoxetine was a reaction to the side-effect of akathisia (i.e., unbearable discomfort and restlessness) and not true suicidal ideation as is typically described by depressed patients experiencing suicidal ideation."
Dr Joseph Glenmullen, author of "Prozac Backlash" and "The Antidepressant Solution," obtained a Lilly document dated November 13, 1990, from Claude Bouchy, a Lilly employee in Germany, to three executives at Lilly's Indianapolis headquarters, complaining about directions to change the identification of events as they are reported to doctors from "suicide attempt" to "overdose" and "suicidal ideation" to "depression".
"I do not think I could explain to the BGA, to a judge, to a reporter or even to my family," Mr Bouchy wrote, "why we would do this especially on the sensitive issue of suicide and suicide ideation."
Dr Glenmullen says akathisia makes people profoundly agitated, uncomfortable in their own skin and impulsive. It erodes judgment and can lower their threshold to become violent toward themselves or others, he states.
Dr Martin Teicher, an associate professor at Harvard Medical School and McLean Hospital researcher at the time, co-authored a paper with psychiatrist and psychopharmacologist Jonathan Cole on the link between Prozac and suicide back in 1990, which found that 3.5% of patients on Prozac either attempted or committed suicide due to severe agitation from akathisia.
In the paper, the authors discussed 6 cases of patients who became intensely preoccupied with suicide after taking Prozac. Dr Cole said, in an affidavit submitted in litigation on April 20, 2000, "Our purpose in writing this article was to alert the profession to an alarming, probable drug side effect which we had observed."
"There was a very clear association," he said, "not merely temporal, between the ingestion of Prozac and the patients' suicidality."
"I have also seen patients and reviewed cases," Dr Cole stated, "where an SSRI unmistakably precipitated a driven preoccupation with suicide."
"The SSRI drugs, as a class," he advised, "clearly have the potential to cause, and in reasonable medical probability or certainty do cause, akathisia in some patients."
"Although in 1997," Dr Cole notes, "practicing physicians undoubtedly varied in their level of sophistication and knowledge about the phenomenon, the potential to cause akathisia and its potential, in turn, to trigger suicidal behavior."
Additional evidence showing Lilly knew about the akathisia-induced suicide surfaced in an application for a patent for a second-generation Prozac pill which claimed that the new-and-improved Prozac would decrease the side effects of, "inner restlessness (akathisia), suicidal thoughts and self-mutilation."
Besides the concealment of this adverse effect by the drug companies, another major problem in getting the word out, according to Vince Boehm, who tracks all studies and research published on SSRI's, is that the FDA refuses to fully acknowledge the role of drug-induced akathisia in what he refers to as "this hideous equation."
"Akathisia is up to 6 times more likely to trigger a suicide," he states, "than any form of depression caused by life's circumstances alone."
"The minds inner turmoil is so intense that a person will do anything to escape it," he says.
"The Brits, the Aussies, Canada, and the European Union," he points out, "have all gone on record recognizing this phenomenon for all age groups."
Judging by internal FDA documents which have surfaced in litigation, Mr Boehm appears to be correct. For instance, in a September 11, 1990, memo, FDA scientist Dr David Graham found that Lilly's data on Prozac was insufficient to prove the drug was safe, stating: "Because of apparent large-scale underreporting, the firm's analysis cannot be considered as proving that fluoxetine and violent behavior are unrelated."
A more recent study in the September 2006 journal Public Library of Science (PLoS) has further verified the warnings made by many other experts, when it reported that, in addition to self-harm, SSRI's cause some patients to become violent and homicidal.
Dr David Healy, described as "one of the three most eminent academic clinical psychiatrists in the UK," professor David Menkes, from Cardiff University in Britain, and Andrew Herxheimer, from the Cochrane Centre, did the study to determine the risk of violent behavior in people taking SSRI's.
As part of their investigation, the researchers reviewed all available clinical data on SSRI's and summarized a series of "medico-legal" court cases involving patients who had became violent on SSRI's.
One case discussed dated back to 2001, when Dr Healy testified at a wrongful death trial in Wyoming, after a 60-year-old man on Paxil shot and killed his wife, daughter and infant granddaughter before turning the gun on himself in 1998.
At trial, the jury returned a verdict for the man's son-in-law after Dr Healy presented the jury with a summary of an unpublished company study that found incidents of serious aggression in 80 patients on Paxil, including 25 that involved homicide, and proved that the drug maker knew about the violence and suicide risks before the 1998 shootings.
Dr Healy points out a rechallenge study by Rothschild and Locke in McLean Hospital where the authors found Prozac-induced emergent suicidality associated with akathisia in several patients. In order to test whether suicidality was coincidental or associated with Prozac, they withdrew Prozac, then re-administered it, and in all three cases, the patients experienced the exact same effect. "All three patients developed severe akathisia during treatment with fluoxetine and stated that the development of the akathisia made them feel suicidal and that it had precipitated their prior suicide attempts."
However, even more alarming, one set of patients who became suicidal on Prozac were described as follows: "[n]one had a history of significant suicidal behavior; all described their distress as an intense and novel somatic-emotional state; all reported an urge to pace that paralleled the intensity of the distress; all experienced suicidal thoughts at the peak of their restless agitation; and all experienced a remission of their agitation, restlessness, pacing urge, and suicidality after the fluoxetine was discontinued."
It's Time To Sue Doctors Who Prescribe Drugs Off-Label - Part I
Evelyn Pringle August 15, 2007
Critics say the tens of thousands of lawsuits filed against the drug giants have had little impact when it comes to dismantling the off-label drug marketing schemes and therefore, there needs to be an all out campaign of highly publicized lawsuits filed against the doctors serving as middle man pushers, one by one by one.
It is illegal for a drug company to promote a drug for uses not listed on the FDA-approved label for the simple reason that the drug maker has not successfully proven to the FDA that the drug is safe or effective for uses not listed on the label.
However, because of a legal loophole wider than a barn door, doctors have the authority to prescribe a drug for an unapproved use if they believe a patient would benefit, which means all a drug maker has to do is find doctors willing to promote the off-label uses and deny the drug company's involvement in the scheme.
And recent studies on prescribing habits have shown that the drug companies have found thousands of doctors all across the US in every field of medicine more than willing to participate in drugging for profit schemes by writing prescriptions that result in fees paid for monthly office visits that require no more than a few minutes of the doctor's time.
Critics says the first round of lawsuits should be filed against the quacks involved in prescribing psychiatric drugs to millions of children who are now stigmatized for life by a label of mental illness and will face a life-time of discrimination in finding jobs and obtaining health insurance due to a trail of medical records showing a history of taking drugs used to treat the most severe mental illnesses of major depression, bipolar disorder and schizophrenia.
Critics point out that doctors in fields of medicine that have never before involved the diagnosing and treatment of mental illness would never have come up with the idea to prescribe psychiatric drugs off-label to children without the illegal prompting from the drug makers.
For example, on June 20, 2004, the Florida Sun-Sentinel reported that a review of Medicaid records in that state found doctors with specialties in dermatology, nutrition, anesthesiology, ophthalmology, allergy, radiology, plastic surgery, hematology, obstetrics, pathology, diabetes, rheumatology, and hand surgery wrote prescriptions for psychotropic drugs for children aged 12 and younger between September 2002 to September 2003.
In record numbers, children are being fed powerful psychiatric drugs, often in combination with each other, including selective serotonin reuptake inhibitor antidepressants like Paxil, Cymbalta, Lexapro, Celexa, Prozac, and Zoloft and the new generation of "atypical" antipsychotics, such as Zyprexa, Risperdal, Geodon, Seroquel, Clozaril, and Abilify.
Children are also receiving drugs for ADHD in record numbers including the stimulants Adderall, Dexedrine and Ritalin, often combined with drugs approved only to treat adults with epilepsy such as Depakote and Neurontin.
Experts say its not uncommon to see children on an SSRI, an antipsychotic, a stimulant drug, and a sleeping medication all at the same time. Neurologist, Dr Fred Baughman, author of, The ADHD Fraud, warns that multiple drugs are being prescribed together in combinations that are lacking of any scientific basis.
Most critics say the ever-expanding list of invented disorders is the driving force behind this mass-drugging for profit. "While the drug companies certainly are getting rich providing mind-altering drugs for psychiatry's made-up mental disorders, the fault for the fraud of psychiatric diagnosing lies with the psychiatric community," says investigative journalist, Kelly Patricia O'Meara, author of "PSYCHED OUT: How Psychiatry Sells Mental Illness and Pushes Pills That Kill".
Harvard Instructor Dr John Abramson, author of, "Overdosed America," calls it a "progressive medicalization" of undesirable behavior in children. "We have seen this in the enormous proliferation of stimulant medication use," he notes, "far out of proportion to use in other countries."
Now the diagnosis of bipolar disorder in children is rising in parallel, he says, and clearly it is the drug industry driving this medicalization to sell more products.
Other experts agree. On February 15, 2007, the New York Times reported comments by Dr Bessel van der Kolk, a professor of psychiatry at Boston University who also treats children at a trauma clinic. "Most of the patients I see who have been misdiagnosed," she said, "have been told they have bipolar disorder."
"The diagnosis is made with no understanding of the context of their life," she said. "Then they're put on these devastating medications and condemned to a life as a psychiatry patient."
Former Clinical Director of Kingsboro Psychiatric Center in Brooklyn, Dr Nathaniel Lehrman also says, "relying on medication as the definitive treatment of psychiatric complaints, rather than addressing their real causes in patients' lives, is responsible for the gross overuse of psychiatric medications, especially among children."
He is especially critical of the ADHD diagnosis. "Its "symptoms" acting impulsively; easy distractibility; interrupting others; constant fidgeting or moving; and difficulty in paying attention, waiting one's turn, planning ahead, following instructions, or meeting deadlines, can be found in any of us," Dr Lehrman points out.
A study in the August 3, 2004 Archives of Pediatric Adolescent Medicine reported that the rate of antipsychotics use by children covered by a public health care program in Tennessee had nearly doubled between 1996 and 2001, and had increased 61% with preschoolers.
A review of Medicaid records in Ohio for the month of July 2004, found 18 newborn to 3 year-old babies had been prescribed antipsychotics and 28 more in the same age group were on antidepressants, according to the April 25, 2005 Columbus Dispatch.
According to the December 2006 Special Report entitled, "Foster Children - Texas Health Care Claims Study," in 2004, psychotropic drugs accounted for more than 76% of the cost of all medications prescribed to foster children in Texas on Medicaid.
Of all drugs prescribed, the study found antidepressants, antipsychotics and stimulants were the most frequently prescribed and half of the children in a sample of 472, received 3 or more drugs from different classes at the same time and 27.5% received 4 or more, with antidepressants and antipsychotics being the two most commonly prescribed together.
The same year, Texas also spent nearly $4.8 million on nearly 43,000 anticonvulsants used as mood stabilizers for about 4,500 foster children, including 133 aged four and younger, as well as close to $4.5 million on 45,318 stimulant prescriptions for more than 6,500 foster children including nearly 200 who were aged 4 and under.
There were also nearly 2,500 prescriptions written for hypnotic/sedative drugs for about 1,000 foster children, including 232 four and younger to treat anxiety or sleep disorders.
In addition, more than 400 of the foster children were prescribed antidyskinetics drugs to control side effects caused by the antipsychotics which included tremors, tics, dystonia, dyskinesia and tardive dyskinesia.
Last year in Florida, Medicaid records show that more than 1,100 children 6 and under were prescribed antipsychotics at a cost to Medicaid of nearly $1,800 per child and most were prescribed to treat mood disorders, depression, anxiety or ADHD. In addition, 367 Florida toddlers 3 and under were prescribed ADHD drugs in 2006.
The debate about the over-drugging of children has been festering behind the scenes for a decade, but the all-out war between medical professionals recently exposed in the media is the result of the widespread outrage over the highly publicized overdose death of the 4-year-old toddler, Rebecca Riley in Hull, Massachusetts in December 2006.
The outrage began when the police investigation revealed that Rebecca was given the diagnoses of ADHD and bipolar disorder by Dr Kayoko Kifuji, at the Tufts-New England Medical Center, when she was only 2 and half-years-old and placed on a 3-drug cocktail of Clonidine, a drug approved to treat adults with high blood pressure, Depakote an antiseizure drug approved to treat adults with epilepsy, and Seroquel, approved to treat adults with schizophrenia or the mania of bipolar disorder.
Investigators also reported that Dr Kifuji had diagnosed Rebecca's 6-year-old sister and 11-year-old brother with the same disorders and kept them on the same 3-drug cocktail even longer than Rebecca. The mother and father were also diagnosed mentally ill and the whole family was covered by Medicaid, according to police reports.
In a June 17, 2007 report in the Boston Globe, reporter Scott Allen discussed Rebecca's death and the rising dissent within the medical profession. Under the headline, "Backlash on bipolar diagnoses in children," he noted that psychiatrist, Dr Joseph Biederman of Massachusetts General Hospital, "could be credited more than any other" for convincing Americans that even small children can develop bipolar disorder.
"From his perch as one of the world's most influential child psychiatrists," Mr Allen wrote, "Biederman has spread far and wide his conviction that the emotional roller coaster of bipolar disorder can start "from the moment the child opened his eyes" at birth."
Critics also identify Dr Janet Wozniak, director of the Pediatric Bipolar Disorder Research Program at Massachusetts General, as a researcher who has worked side by side with Dr Biederman to promote the bipolar diagnosis for children.
On June 19, 2007, pediatrician, Dr Lawrence Diller, author of "Should I Medicate My Child," publicly denounced their research and what he called "misguided standards of care" in an editorial in the Boston Globe and informed the world that he had recently done "the nearly unthinkable" at a medical conference on bipoloar disorder in children.
"I charged another doctor," he stated, "with moral responsibility in the death last December of Rebecca Riley, a 4-year-old girl from Hull."
He acknowledged that he understood the risks of naming names. "Yet I felt compelled," he said, "to name Joseph Biederman, head of the Massachusetts General Hospital's Pediatric Psychopharmacology clinic, as morally culpable in providing the "science" that allowed Rebecca to die."
According to Dr Diller, Dr Biederman shocked the child psychiatric world in 1996 by announcing that nearly a quarter of the kids he was treating for attention deficit disorder also met his criteria for bipolar disorder. "Up until then," he says, "bipolar disorder was rarely diagnosed in teenagers and unheard of in prepubertal children."
Dr Diller says there are thousands of potential Rebecca Rileys being treated with multiple psychiatric drugs because Dr Biederman has said it's OK and necessary.
Critics say the tens of thousands of lawsuits filed against the drug giants have had little impact when it comes to dismantling the off-label drug marketing schemes and therefore, there needs to be an all out campaign of highly publicized lawsuits filed against the doctors serving as middle man pushers, one by one by one.
It is illegal for a drug company to promote a drug for uses not listed on the FDA-approved label for the simple reason that the drug maker has not successfully proven to the FDA that the drug is safe or effective for uses not listed on the label.
Critics say the tens of thousands of lawsuits filed against the drug giants have had little impact when it comes to dismantling the off-label drug marketing schemes and therefore, there needs to be an all out campaign of highly publicized lawsuits filed against the doctors serving as middle man pushers, one by one by one.
It is illegal for a drug company to promote a drug for uses not listed on the FDA-approved label for the simple reason that the drug maker has not successfully proven to the FDA that the drug is safe or effective for uses not listed on the label.
However, because of a legal loophole wider than a barn door, doctors have the authority to prescribe a drug for an unapproved use if they believe a patient would benefit, which means all a drug maker has to do is find doctors willing to promote the off-label uses and deny the drug company's involvement in the scheme.
And recent studies on prescribing habits have shown that the drug companies have found thousands of doctors all across the US in every field of medicine more than willing to participate in drugging for profit schemes by writing prescriptions that result in fees paid for monthly office visits that require no more than a few minutes of the doctor's time.
Critics says the first round of lawsuits should be filed against the quacks involved in prescribing psychiatric drugs to millions of children who are now stigmatized for life by a label of mental illness and will face a life-time of discrimination in finding jobs and obtaining health insurance due to a trail of medical records showing a history of taking drugs used to treat the most severe mental illnesses of major depression, bipolar disorder and schizophrenia.
Critics point out that doctors in fields of medicine that have never before involved the diagnosing and treatment of mental illness would never have come up with the idea to prescribe psychiatric drugs off-label to children without the illegal prompting from the drug makers.
For example, on June 20, 2004, the Florida Sun-Sentinel reported that a review of Medicaid records in that state found doctors with specialties in dermatology, nutrition, anesthesiology, ophthalmology, allergy, radiology, plastic surgery, hematology, obstetrics, pathology, diabetes, rheumatology, and hand surgery wrote prescriptions for psychotropic drugs for children aged 12 and younger between September 2002 to September 2003.
In record numbers, children are being fed powerful psychiatric drugs, often in combination with each other, including selective serotonin reuptake inhibitor antidepressants like Paxil, Cymbalta, Lexapro, Celexa, Prozac, and Zoloft and the new generation of "atypical" antipsychotics, such as Zyprexa, Risperdal, Geodon, Seroquel, Clozaril, and Abilify.
Children are also receiving drugs for ADHD in record numbers including the stimulants Adderall, Dexedrine and Ritalin, often combined with drugs approved only to treat adults with epilepsy such as Depakote and Neurontin.
Experts say its not uncommon to see children on an SSRI, an antipsychotic, a stimulant drug, and a sleeping medication all at the same time. Neurologist, Dr Fred Baughman, author of, The ADHD Fraud, warns that multiple drugs are being prescribed together in combinations that are lacking of any scientific basis.
Most critics say the ever-expanding list of invented disorders is the driving force behind this mass-drugging for profit. "While the drug companies certainly are getting rich providing mind-altering drugs for psychiatry's made-up mental disorders, the fault for the fraud of psychiatric diagnosing lies with the psychiatric community," says investigative journalist, Kelly Patricia O'Meara, author of "PSYCHED OUT: How Psychiatry Sells Mental Illness and Pushes Pills That Kill".
Harvard Instructor Dr John Abramson, author of, "Overdosed America," calls it a "progressive medicalization" of undesirable behavior in children. "We have seen this in the enormous proliferation of stimulant medication use," he notes, "far out of proportion to use in other countries."
Now the diagnosis of bipolar disorder in children is rising in parallel, he says, and clearly it is the drug industry driving this medicalization to sell more products.
Other experts agree. On February 15, 2007, the New York Times reported comments by Dr Bessel van der Kolk, a professor of psychiatry at Boston University who also treats children at a trauma clinic. "Most of the patients I see who have been misdiagnosed," she said, "have been told they have bipolar disorder."
"The diagnosis is made with no understanding of the context of their life," she said. "Then they're put on these devastating medications and condemned to a life as a psychiatry patient."
Former Clinical Director of Kingsboro Psychiatric Center in Brooklyn, Dr Nathaniel Lehrman also says, "relying on medication as the definitive treatment of psychiatric complaints, rather than addressing their real causes in patients' lives, is responsible for the gross overuse of psychiatric medications, especially among children."
He is especially critical of the ADHD diagnosis. "Its "symptoms" acting impulsively; easy distractibility; interrupting others; constant fidgeting or moving; and difficulty in paying attention, waiting one's turn, planning ahead, following instructions, or meeting deadlines, can be found in any of us," Dr Lehrman points out.
A study in the August 3, 2004 Archives of Pediatric Adolescent Medicine reported that the rate of antipsychotics use by children covered by a public health care program in Tennessee had nearly doubled between 1996 and 2001, and had increased 61% with preschoolers.
A review of Medicaid records in Ohio for the month of July 2004, found 18 newborn to 3 year-old babies had been prescribed antipsychotics and 28 more in the same age group were on antidepressants, according to the April 25, 2005 Columbus Dispatch.
According to the December 2006 Special Report entitled, "Foster Children - Texas Health Care Claims Study," in 2004, psychotropic drugs accounted for more than 76% of the cost of all medications prescribed to foster children in Texas on Medicaid.
Of all drugs prescribed, the study found antidepressants, antipsychotics and stimulants were the most frequently prescribed and half of the children in a sample of 472, received 3 or more drugs from different classes at the same time and 27.5% received 4 or more, with antidepressants and antipsychotics being the two most commonly prescribed together.
The same year, Texas also spent nearly $4.8 million on nearly 43,000 anticonvulsants used as mood stabilizers for about 4,500 foster children, including 133 aged four and younger, as well as close to $4.5 million on 45,318 stimulant prescriptions for more than 6,500 foster children including nearly 200 who were aged 4 and under.
There were also nearly 2,500 prescriptions written for hypnotic/sedative drugs for about 1,000 foster children, including 232 four and younger to treat anxiety or sleep disorders.
In addition, more than 400 of the foster children were prescribed antidyskinetics drugs to control side effects caused by the antipsychotics which included tremors, tics, dystonia, dyskinesia and tardive dyskinesia.
Last year in Florida, Medicaid records show that more than 1,100 children 6 and under were prescribed antipsychotics at a cost to Medicaid of nearly $1,800 per child and most were prescribed to treat mood disorders, depression, anxiety or ADHD. In addition, 367 Florida toddlers 3 and under were prescribed ADHD drugs in 2006.
The debate about the over-drugging of children has been festering behind the scenes for a decade, but the all-out war between medical professionals recently exposed in the media is the result of the widespread outrage over the highly publicized overdose death of the 4-year-old toddler, Rebecca Riley in Hull, Massachusetts in December 2006.
The outrage began when the police investigation revealed that Rebecca was given the diagnoses of ADHD and bipolar disorder by Dr Kayoko Kifuji, at the Tufts-New England Medical Center, when she was only 2 and half-years-old and placed on a 3-drug cocktail of Clonidine, a drug approved to treat adults with high blood pressure, Depakote an antiseizure drug approved to treat adults with epilepsy, and Seroquel, approved to treat adults with schizophrenia or the mania of bipolar disorder.
Investigators also reported that Dr Kifuji had diagnosed Rebecca's 6-year-old sister and 11-year-old brother with the same disorders and kept them on the same 3-drug cocktail even longer than Rebecca. The mother and father were also diagnosed mentally ill and the whole family was covered by Medicaid, according to police reports.
In a June 17, 2007 report in the Boston Globe, reporter Scott Allen discussed Rebecca's death and the rising dissent within the medical profession. Under the headline, "Backlash on bipolar diagnoses in children," he noted that psychiatrist, Dr Joseph Biederman of Massachusetts General Hospital, "could be credited more than any other" for convincing Americans that even small children can develop bipolar disorder.
"From his perch as one of the world's most influential child psychiatrists," Mr Allen wrote, "Biederman has spread far and wide his conviction that the emotional roller coaster of bipolar disorder can start "from the moment the child opened his eyes" at birth."
Critics also identify Dr Janet Wozniak, director of the Pediatric Bipolar Disorder Research Program at Massachusetts General, as a researcher who has worked side by side with Dr Biederman to promote the bipolar diagnosis for children.
On June 19, 2007, pediatrician, Dr Lawrence Diller, author of "Should I Medicate My Child," publicly denounced their research and what he called "misguided standards of care" in an editorial in the Boston Globe and informed the world that he had recently done "the nearly unthinkable" at a medical conference on bipoloar disorder in children.
"I charged another doctor," he stated, "with moral responsibility in the death last December of Rebecca Riley, a 4-year-old girl from Hull."
He acknowledged that he understood the risks of naming names. "Yet I felt compelled," he said, "to name Joseph Biederman, head of the Massachusetts General Hospital's Pediatric Psychopharmacology clinic, as morally culpable in providing the "science" that allowed Rebecca to die."
According to Dr Diller, Dr Biederman shocked the child psychiatric world in 1996 by announcing that nearly a quarter of the kids he was treating for attention deficit disorder also met his criteria for bipolar disorder. "Up until then," he says, "bipolar disorder was rarely diagnosed in teenagers and unheard of in prepubertal children."
Dr Diller says there are thousands of potential Rebecca Rileys being treated with multiple psychiatric drugs because Dr Biederman has said it's OK and necessary.
Critics say the tens of thousands of lawsuits filed against the drug giants have had little impact when it comes to dismantling the off-label drug marketing schemes and therefore, there needs to be an all out campaign of highly publicized lawsuits filed against the doctors serving as middle man pushers, one by one by one.
It is illegal for a drug company to promote a drug for uses not listed on the FDA-approved label for the simple reason that the drug maker has not successfully proven to the FDA that the drug is safe or effective for uses not listed on the label.
It's Time To Sue Doctors Who Prescribe Drugs Off-Label - Part II
Evelyn Pringle August 17, 2007
Experts say the serious side effects associated with the use of the 3-drug cocktail of Seroquel, Depakote and Clonidine prescribed to Rebecca Riley when she was 2 and a half-years-old that resulted in her slow and torturous death two and a-half-years later should be known to all prescribing doctors by now.
According to police reports, Rebecca was under the care of Dr Kayoko Kifuji, at the Tufts-New England Medical Center, and her mother said Dr Kifuji prescribed Depakote to control Rebecca's mood, at a dose of 3 capsules in the morning and 3 capsules at night, administered by breaking the capsules open and sprinkling the contents on her tongue.
She said Seroquel was prescribed to help calm Rebecca and to help her stay asleep and she received 25 mg in the morning and 175 mg at night. Clonidine was also prescribed to help her calm down and sleep and was given at a dose of .1 mg tablets, divided in half so that Rebecca took a half tablet in the morning, a half tablet at noon, a half tablet at 3:00 pm and two full tablets at bedtime, according to the police report.
Experts say this combination of drugs has never even been studied in animals much less humans. As far back as September 2003, University of Maryland researcher Julie Magno Zito, said in an interview with Mother Jones Magazine, that she was surprised to discover that the new antipsychotics were being used to treat kids who "act out," and was also worried about Clonidine, a blood pressure drug that was being given to children with ADHD, and even to "sleep resistant" babies, she said.
Clonidine is among the top 5 psychotropic drugs used with children, Dr Zito said, and yet, "no one is tracking what effect it may have on a child's cardiovascular system to take a drug that speeds up the heart, often along with one that slows it down," she warned.
Poison centers nationwide are receiving increasing reports of children suffering toxic effects from Clonidine, according to a University of Maryland School of Pharmacy study. "This is a really potent drug that can have an adverse effect at a dose as small as one pill," says the study's author Wendy Klein-Schwartz.
The new "atypical" antipsychotics include AstraZeneca's Seroquel, Eli Lilly's Zyprexa, Abilify by Bristol-Myers Squibb, Johnson & Johnson's Risperdal and Geodon by Pfizer.
According to Scott Allen's report in the June 17, 2007, Boston Globe, "Psychiatrists used to regard bipolar disorder as a disease that begins in young adulthood, but now some diagnose it in children scarcely out of diapers, treating them with powerful antipsychotic medications based on Biederman's work."
In 2001, he says, the Massachusetts General researchers published what he refers to as another "enormously influential" study in the Journal of Child and Adolescent Psychopharmacology which included 23 children who were diagnosed with bipolar disorder and given Zyprexa for 8 weeks.
The researchers reported that Zyprexa lessened the outbreaks of aggression but the children typically gained more than 10 pounds, according to Mr Allen. He says this study went on to become one of the most frequently quoted articles in the history of the Journal.
Rebecca's death is not a rare occurrence for children on these drugs. A May 10, 2007, report in the New York Times said in 2006 alone, the FDA received reports of at least 29 children dying and at least 165 more reports of other serious side effects in children where an antipsychotic was listed as the "primary suspect."
Neurologist Dr Fred Baughman, author of "The ADHD Fraud," blames Rebecca's doctor and says misdiagnosing patients for profit is criminal. "As a neurologist," he say, "it was my duty to diagnose the neurological consequences of these drugs and only one to 2% of all antipsychotics prescribed might be justifiable, if that."
He points out that Rebecca's death was not the result of science gone wrong. "It was flatly, plainly, criminal," he says, "and the criminals must be indicted, tried and sentenced."
In an affidavit filed in Rebecca's case, a state trooper reported that no testing was conducted to make the diagnosis of attention deficit and bipolar disorders and that Dr Kayoko Kifuji, at the Tufts-New England Medical Center, said she based her diagnoses on the "family mental illness history" as described by the mother and "Rebecca's behavior" as described by the mother and "briefly observed" by Dr Kifuji during office visits, which "occurred from every two weeks to every other month and Rebecca's two older siblings were also seen," the trooper states.
The police reports describe kids who were drugged into oblivion. The neighbors said the Riley children were "zomebielike" and "robotic" and the staff at Rebecca's school said she was like a "floppy doll," with tremors so bad that she could barely stand up.
The reports reveal that Rebecca's teacher had repeatedly contacted the school nurse because she was so concerned over her flat affect and shakiness since the spring of 2006.
The school principal told police that she had to assist Rebecca with getting off the bus and walking up the stairs into the school several times because the child was shaking so much that she afraid she would fall and also reported that Rebecca's face and hands were notably swollen and puffy, the reports says.
The trooper's affidavit notes that Dr Kifuji had received several calls from a therapist and the nurse at Rebecca's school saying they were concerned about her medication and the serious side effects they were observing.
A teacher and the nurse told police that Rebecca had a constant need to urinate but would void very little and was so weak that she could often not zip up her pants when she was done and that Dr Kifuji said the constant need to urinate was caused by the medication. They also told police that they had not observed any behaviors in Rebecca that would indicate that she had ADHD or bipolar disorder.
In a June 19, 2007, editorial in the Globe, pediatrician Dr Lawrence Diller said Rebecca's death was the last straw and it was time to direct the blame where it belongs. "Biederman and his colleagues at Harvard," he wrote, "are the professionals most responsible for developing and promoting those standards of care -- which include diagnosing preschool children as young as 2 with bipolar disorder and treating them with multiple medications."
"Supported by millions of dollars of drug industry promotional funding," he says, "Biederman and his colleagues circle the globe offering professional medical "education" for their singular point of view."
Dr Diller's claim that doctors are influenced by research at Mass General certainly holds true in Rebecca's case, because Dr Kifuji said she was influenced by the work of the Dr Biederman, according to Mr Allen's report. In fact, her attorney, J W Carney Jr, is quoted in the Globe as stating, "They are by far the leading lights in terms of providing leadership in the treatment of children who have disorders such as bipolar."
However, if these researchers are indeed the "leading lights," recent reports in the media about the money flowing to Dr Biederman and Mass General indicate that the drug companies are paying the electric bills.
According Mr Allen's report, Dr Biederman has received research grants from 15 drug makers and serves as a paid speaker or adviser to seven, including Zyprexa maker Eli Lilly and Risperdal maker Janssen.
And in May, 2007, Lilly released a report, no doubt prompted by the investigation by the Senate Finance Committee into the "educational grants," involved in the off-label marketing of Zyprexa, that lists the money that Lilly paid out during the first 3 months of 2007, and the largest grant of $825,000 went to Mass General's psychiatry department.
A report in the August 4, 2007, New York Times identifies Dr Melissa DelBello, of the University of Cincinnati, as having a role in fueling the widespread use of antipsychotics by touting studies funded by AstraZeneca which the Times says were "inconclusive, but she has described them as demonstrating that Seroquel is effective in some children."
When the Times asked Dr DelBellow how much she was paid by AstraZeneca to help market Seroquel, she said, "Trust me, I don't make very much."
The Senate Finance Committee is investigating the payments by drug companies to doctors and researchers like Dr DelBello and this month, Senator Charles Grassley (R-Iowa), introduced legislation that would require drug makers to disclose all payments made to doctors who bill the Medicare and Medicaid programs for services.
In his speech on the Senate floor, Senator Grassley listed Dr DelBellow as an example of why the legislation is necessary. After reading the Times article where she said she did not make much, Senator Grassley checked out her disclosure forms at the University and found that she had received $100,000 from AstraZeneca in 2003, and $80,000 in 2004. She also consults for 7 other drug makers, according to the Times on August 4, 2007.
Rebecca's parents have been charged with murder and accused of overmedicating their daughter to sedate her in the 2 days before her death. However, the official autopsy report says Rebecca died of the "combined effects" of the drugs, and that her lungs and heart were damaged by "prolonged abuse of these prescription drugs, rather than one incident."
At the time of her death, there were also over-the-counter cold medicines in Rebecca's body including Children's Tylenol Cough and Runny Nose, which contain acetaminophen, dextromethorphan and chlorpheniramine and a highly respected expert on psychiatric drugs, Dr Grace Jackson, author of Rethinking Psychiatric Drugs, says Rebecca most likely died as a result of a largely unrecognized condition called serotonin syndrome caused by the many different drugs in her system.
"In this case," Dr Jackson says, "the primary culprits were dextromethorphan and chlorpheniramine, an antihistamine which also boosts serotonin levels."
"It is probably quite likely," she explains, "that the family had not been warned by any doctor or pharmacist that this combination of medications could cause death - particularly, in a toddler."
In the days before Rebecca died, observations reported to investigators describe behaviors common with serotonin syndrome including that she appeared dazed and disorientated and became incoherent and would not respond to her own name.
Through their attorneys, the parents have accused Dr Kifuji of over-prescribing and the doctor's license has been suspended while the state's medical board investigates the case.
After Rebecca's death, the Massachusetts Department of Social Services sought an independent opinion from doctors at Children's Hospital in Boston for her brother and sister and determined that their medication needed to be changed.
According to Mr Allen, state officials have also stepped up a review of 8,343 more children on Medicaid in Massachusetts who are on antipsychotics to determine whether the treatment is appropriate.
Experts say the serious side effects associated with the use of the 3-drug cocktail of Seroquel, Depakote and Clonidine prescribed to Rebecca Riley when she was 2 and a half-years-old that resulted in her slow and torturous death two and a-half-years later should be known to all prescribing doctors by now.
According to police reports, Rebecca was under the care of Dr Kayoko Kifuji, at the Tufts-New England Medical Center, and her mother said Dr Kifuji prescribed Depakote to control Rebecca's mood, at a dose of 3 capsules in the morning and 3 capsules at night, administered by breaking the capsules open and sprinkling the contents on her tongue.
She said Seroquel was prescribed to help calm Rebecca and to help her stay asleep and she received 25 mg in the morning and 175 mg at night. Clonidine was also prescribed to help her calm down and sleep and was given at a dose of .1 mg tablets, divided in half so that Rebecca took a half tablet in the morning, a half tablet at noon, a half tablet at 3:00 pm and two full tablets at bedtime, according to the police report.
Experts say this combination of drugs has never even been studied in animals much less humans. As far back as September 2003, University of Maryland researcher Julie Magno Zito, said in an interview with Mother Jones Magazine, that she was surprised to discover that the new antipsychotics were being used to treat kids who "act out," and was also worried about Clonidine, a blood pressure drug that was being given to children with ADHD, and even to "sleep resistant" babies, she said.
Clonidine is among the top 5 psychotropic drugs used with children, Dr Zito said, and yet, "no one is tracking what effect it may have on a child's cardiovascular system to take a drug that speeds up the heart, often along with one that slows it down," she warned.
Poison centers nationwide are receiving increasing reports of children suffering toxic effects from Clonidine, according to a University of Maryland School of Pharmacy study. "This is a really potent drug that can have an adverse effect at a dose as small as one pill," says the study's author Wendy Klein-Schwartz.
The new "atypical" antipsychotics include AstraZeneca's Seroquel, Eli Lilly's Zyprexa, Abilify by Bristol-Myers Squibb, Johnson & Johnson's Risperdal and Geodon by Pfizer.
According to Scott Allen's report in the June 17, 2007, Boston Globe, "Psychiatrists used to regard bipolar disorder as a disease that begins in young adulthood, but now some diagnose it in children scarcely out of diapers, treating them with powerful antipsychotic medications based on Biederman's work."
In 2001, he says, the Massachusetts General researchers published what he refers to as another "enormously influential" study in the Journal of Child and Adolescent Psychopharmacology which included 23 children who were diagnosed with bipolar disorder and given Zyprexa for 8 weeks.
The researchers reported that Zyprexa lessened the outbreaks of aggression but the children typically gained more than 10 pounds, according to Mr Allen. He says this study went on to become one of the most frequently quoted articles in the history of the Journal.
Rebecca's death is not a rare occurrence for children on these drugs. A May 10, 2007, report in the New York Times said in 2006 alone, the FDA received reports of at least 29 children dying and at least 165 more reports of other serious side effects in children where an antipsychotic was listed as the "primary suspect."
Neurologist Dr Fred Baughman, author of "The ADHD Fraud," blames Rebecca's doctor and says misdiagnosing patients for profit is criminal. "As a neurologist," he say, "it was my duty to diagnose the neurological consequences of these drugs and only one to 2% of all antipsychotics prescribed might be justifiable, if that."
He points out that Rebecca's death was not the result of science gone wrong. "It was flatly, plainly, criminal," he says, "and the criminals must be indicted, tried and sentenced."
In an affidavit filed in Rebecca's case, a state trooper reported that no testing was conducted to make the diagnosis of attention deficit and bipolar disorders and that Dr Kayoko Kifuji, at the Tufts-New England Medical Center, said she based her diagnoses on the "family mental illness history" as described by the mother and "Rebecca's behavior" as described by the mother and "briefly observed" by Dr Kifuji during office visits, which "occurred from every two weeks to every other month and Rebecca's two older siblings were also seen," the trooper states.
The police reports describe kids who were drugged into oblivion. The neighbors said the Riley children were "zomebielike" and "robotic" and the staff at Rebecca's school said she was like a "floppy doll," with tremors so bad that she could barely stand up.
The reports reveal that Rebecca's teacher had repeatedly contacted the school nurse because she was so concerned over her flat affect and shakiness since the spring of 2006.
The school principal told police that she had to assist Rebecca with getting off the bus and walking up the stairs into the school several times because the child was shaking so much that she afraid she would fall and also reported that Rebecca's face and hands were notably swollen and puffy, the reports says.
The trooper's affidavit notes that Dr Kifuji had received several calls from a therapist and the nurse at Rebecca's school saying they were concerned about her medication and the serious side effects they were observing.
A teacher and the nurse told police that Rebecca had a constant need to urinate but would void very little and was so weak that she could often not zip up her pants when she was done and that Dr Kifuji said the constant need to urinate was caused by the medication. They also told police that they had not observed any behaviors in Rebecca that would indicate that she had ADHD or bipolar disorder.
In a June 19, 2007, editorial in the Globe, pediatrician Dr Lawrence Diller said Rebecca's death was the last straw and it was time to direct the blame where it belongs. "Biederman and his colleagues at Harvard," he wrote, "are the professionals most responsible for developing and promoting those standards of care -- which include diagnosing preschool children as young as 2 with bipolar disorder and treating them with multiple medications."
"Supported by millions of dollars of drug industry promotional funding," he says, "Biederman and his colleagues circle the globe offering professional medical "education" for their singular point of view."
Dr Diller's claim that doctors are influenced by research at Mass General certainly holds true in Rebecca's case, because Dr Kifuji said she was influenced by the work of the Dr Biederman, according to Mr Allen's report. In fact, her attorney, J W Carney Jr, is quoted in the Globe as stating, "They are by far the leading lights in terms of providing leadership in the treatment of children who have disorders such as bipolar."
However, if these researchers are indeed the "leading lights," recent reports in the media about the money flowing to Dr Biederman and Mass General indicate that the drug companies are paying the electric bills.
According Mr Allen's report, Dr Biederman has received research grants from 15 drug makers and serves as a paid speaker or adviser to seven, including Zyprexa maker Eli Lilly and Risperdal maker Janssen.
And in May, 2007, Lilly released a report, no doubt prompted by the investigation by the Senate Finance Committee into the "educational grants," involved in the off-label marketing of Zyprexa, that lists the money that Lilly paid out during the first 3 months of 2007, and the largest grant of $825,000 went to Mass General's psychiatry department.
A report in the August 4, 2007, New York Times identifies Dr Melissa DelBello, of the University of Cincinnati, as having a role in fueling the widespread use of antipsychotics by touting studies funded by AstraZeneca which the Times says were "inconclusive, but she has described them as demonstrating that Seroquel is effective in some children."
When the Times asked Dr DelBellow how much she was paid by AstraZeneca to help market Seroquel, she said, "Trust me, I don't make very much."
The Senate Finance Committee is investigating the payments by drug companies to doctors and researchers like Dr DelBello and this month, Senator Charles Grassley (R-Iowa), introduced legislation that would require drug makers to disclose all payments made to doctors who bill the Medicare and Medicaid programs for services.
In his speech on the Senate floor, Senator Grassley listed Dr DelBellow as an example of why the legislation is necessary. After reading the Times article where she said she did not make much, Senator Grassley checked out her disclosure forms at the University and found that she had received $100,000 from AstraZeneca in 2003, and $80,000 in 2004. She also consults for 7 other drug makers, according to the Times on August 4, 2007.
Rebecca's parents have been charged with murder and accused of overmedicating their daughter to sedate her in the 2 days before her death. However, the official autopsy report says Rebecca died of the "combined effects" of the drugs, and that her lungs and heart were damaged by "prolonged abuse of these prescription drugs, rather than one incident."
At the time of her death, there were also over-the-counter cold medicines in Rebecca's body including Children's Tylenol Cough and Runny Nose, which contain acetaminophen, dextromethorphan and chlorpheniramine and a highly respected expert on psychiatric drugs, Dr Grace Jackson, author of Rethinking Psychiatric Drugs, says Rebecca most likely died as a result of a largely unrecognized condition called serotonin syndrome caused by the many different drugs in her system.
"In this case," Dr Jackson says, "the primary culprits were dextromethorphan and chlorpheniramine, an antihistamine which also boosts serotonin levels."
"It is probably quite likely," she explains, "that the family had not been warned by any doctor or pharmacist that this combination of medications could cause death - particularly, in a toddler."
In the days before Rebecca died, observations reported to investigators describe behaviors common with serotonin syndrome including that she appeared dazed and disorientated and became incoherent and would not respond to her own name.
Through their attorneys, the parents have accused Dr Kifuji of over-prescribing and the doctor's license has been suspended while the state's medical board investigates the case.
After Rebecca's death, the Massachusetts Department of Social Services sought an independent opinion from doctors at Children's Hospital in Boston for her brother and sister and determined that their medication needed to be changed.
According to Mr Allen, state officials have also stepped up a review of 8,343 more children on Medicaid in Massachusetts who are on antipsychotics to determine whether the treatment is appropriate.
More Scrutiny of Stenting for Profit Industry
Evelyn Pringle August 2007
The stenting for profit industry hit a major snag on March 1, 2007, when the US House Oversight and Government Reform Committee, ordered Johnson & Johnson and Boston Scientific to turn over documents related to their sales and marketing activities for drug-eluting stents.
Drug-eluting stents (DES) are mesh tubes used in patients with heart disease to keep arteries open after a procedures called angioplasty to remove blockage. The new drug-eluding stents were developed to address the problem of restenosis, which prevents renarrowing of the artery. The relative benefits of DES when compared to bare metal stents was supposed to be a reduction of death, heart attack and vessel revascularization.
"Since the new DES arrived on the market, stenting has evolved into a multi-billion dollar industry for the stent makers and doctors and hospitals alike. According to the May 17, 2007 Wall Street Journal, "Americans spent at least $14 billion on coronary-stent procedures last year, including surgical and hospital fees."
Both J&J and Boston have received letters from Committee Chairman, Henry Waxman (D-CA), requesting documents to include correspondence with the FDA. The Committee also wants to know whether the companies used marketing funds to conduct clinical trials and how much researchers were paid and seeks information related to any adverse events revealed in the pre-approval clinical trials, as well as in post-approval use of the products.
In May 2007, after J&J announced that it would withdraw the Conor Medsystem's heart stent from the Indian market after the device failed to complete clinical trials in the US, the Drug Controller General of India raided the company's distributor's office in New Delhi and seized all existing stock of the heart stent, India's drug controller general M Venkateswarlu told the Economic Times on May 10, 2007.
The exact number of Conor stents currently on the market was still being assessed but the Times reports that thousands of patients in India could be at risk because an estimated 8,000 Indian patients have be implanted with the device.
Also the recent "Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE),"study published online on March 26, 2007, by the New England Journal of Medicine showed patients who received stents fared no better than patients who did not.
For the study, led by Dr William Boden of Buffalo General Hospital in New York, half of the roughly 2,300 patients underwent stenting procedures, took heart drugs, and were counseled to make lifestyle changes, such as losing weight, exercising, and giving up smoking and the other half received only lifestyle counseling and drugs to lower cholesterol, relax blood vessels, slow heart rate, and prevent blood clots. After an average of four and a half years, the study found a similar rate of death, heart attack, and stroke in both groups.
In an editorial accompanying the NEJM study, Dr Judith Hochman and Dr Gabriel Steg wrote: "The COURAGE trial should lead to changes in the treatment of patients with stable coronary artery disease, with expected substantial health care savings."
Experts note that there are massive profits at stake. In 2006 alone, combined J&J and Boston earned $3 billion from the devices. On December 4, 2006, Bloomberg News reported that in 2005, the new stents accounted for 52% of total sales for J&J and 43% for Boston.
In July 2007, the stent makers announced their second-quarter earnings and J&J revealed that sales of the Cypher in the US have dropped 41% from this time last year, while Boston released sales figures for its Taxus showing a drop of 42%.
In December 2006, an FDA Advisory Panel determined that off-label use, or using a stent for a purpose outside the device's approved label, is associated with an increased risk of stent thrombosis, death or heart attack compared to approved uses.
Some examples of off-label stenting include use in previously stented patients, patients with diabetes, patients who have stents placed immediately after a heart attack or patients who have stents placed in two arteries which branch off from each other.
Experts say that in the majority of cases the devices are being implanted in patients who could potentially be harmed. According to the FDA, over 60% of DES are being implanted in patients with more complex heart problems than the conditions for which the devices were approved.
With a priced tag of $10,000 to $38,000, as many as 85% of the stenting procedures are non-emergency and are being performed on people with only partially blocked arteries for the relief of recurrent chest pain, according to March 23, 2007 Associated Press.
The first DES was approved in April 2003, and by December 2006, at a hearing on the "Prospective on Drug eluting Stents: Balancing Risks and Benefits," the Advisory Panel reported that 3 out of 5 implants were for unapproved uses.
Dr Ron Waksman presented the results for Contemporary Registries of Washington Hospital Center and reported that the rates of stent thrombosis were almost doubled in cases of off-label use compared to on-label use at 30 days and at 12 months.
He also said that in general, when they looked at on-label and off-label use, "the drug eluting stents are more thrombogenic than bare-metal stents."
For both on-label and off-label use, Dr Waksman said, "over time, late stent thrombosis is seen more in the DES versus the bare-metal stents."
Dr Peter Smith of Duke University told the panel that stenting is being performed on patients with high severity coronary problems such as 3 vessel disease who should be undergoing coronary bypass grafting surgery.
He presented data that showed in these types of cases, 1 out of every 20 patients who died after treatment with stenting would have survived if coronary bypass grafting would have occurred and that DES use in patients with 3 vessel disease results in about 3,600 premature deaths annually in the US.
In the end, the panel did recommend that a warning be added to the DES labels stating that off-label use may increase the risk of thrombosis, myocardial infarction, and death, and several members recommended that a black box warning be added. However, Dr Brian Zuckerman, director of the FDA's division of cardiovascular devices, quickly quashed that idea, saying there would be no black box warning, according to MedPage Today on December 8, 2006.
But as usual, investigations have shown that the FDA was aware of the DES problems for years. Within 6 months of the approval of the first DES, the FDA had already identified 50 cases of allergic reactions and agency records show that a few months after the Cypher arrived on the market, the FDA received a cluster of sub-acute thrombosis reports and the FDA and J&J issued a letter notifying doctors of the initial reports in July 2003.
The Tarus was launched in March 2004, and on July 16, 2004, Boston announced a major recall of 85,000 of the devices after a death and serious injuries were linked to the DES, just two weeks after 200 were recalled following reports of malfunctions during implant procedures. At the time of the announcement, the company also said that it was recalling 11,000 bare metal stent systems, which the FDA found to be linked to two deaths and 25 serious injuries.
Two years later on October 23, 2006, Bloomberg reported that 2.9% of DES patients could develop clots within three years and said, "More than 4 million people have received such stents since 2001, which means clotting related to drug-coated devices may have caused as many as 20,000 heart attacks and 10,000 deaths worldwide."
The American College of Cardiology posted an editorial online by Dr Sanjay Kaul, director of the cardiology fellowship training program at Cedars-Sinai Medical Center and a colleague on October 11, 2006, that warned that blood clots in drug-coated stents may be causing an extra 2,160 deaths in the US alone each year.
The next month, on November 29, 2006 analysis by researchers at the Cleveland Clinic found the risk of blood clots was increased as much as 5-fold in patients who receive drug-coated stents compared to patients implanted with the old bare-metal stents.
"There are hundreds of thousands of Americans who are currently getting stents placed who do not need it as initial therapy," according to Dr Raymond Gibbons, professor of medicine at the Mayo Medical School and president of the American Heart Association, in a United Press International article.
In the March 28, 2007, Wall Street Journal Health Blog, Dr Andy Demajio wrote, "It has been distressing to see how interventional cardiologists have been happily stenting their patients to fatten their wallets."
"This immoral practice should come to a stop," he wrote. In May 2007, the Medicare Strike Force reported that one cardiologist had implanted 25 unnecessary stents in 2006 alone, with most procedures paid for by Medicare.
Legal experts are predicting that future lawsuits filed against Boston and J&J may well include the names of cardiologists and hospitals that helped turn the stenting for profit business into a billion dollar industry. Being there is no way to reverse the stenting procedure, patients face a life-time of worry because a blot clot in a stent can cause a stroke or heart attack without warning at any time.
Lawsuits against the stent makers continue to mount. On December 6, 2007, 46-year-old Sean O'Shea, a man who had five stents implanted, announced a lawsuit against J&J, alleging the company failed to warn him about potential blood clotting complications associated with the stents.
"Had I known there would have been this many complications," he said in a news conference, "I would have chosen other options."
On July 30, 2007, the Zimmerman Reed law firm announced the filing of a lawsuit against J&J by a Minnesota man who suffered a heart attack as a result of a blood clot at the site of his Cypher implant. According to the press release, it is estimated that over 50,000 patients have been implanted with the Cypher stent.
The stenting for profit industry hit a major snag on March 1, 2007, when the US House Oversight and Government Reform Committee, ordered Johnson & Johnson and Boston Scientific to turn over documents related to their sales and marketing activities for drug-eluting stents.
Drug-eluting stents (DES) are mesh tubes used in patients with heart disease to keep arteries open after a procedures called angioplasty to remove blockage. The new drug-eluding stents were developed to address the problem of restenosis, which prevents renarrowing of the artery. The relative benefits of DES when compared to bare metal stents was supposed to be a reduction of death, heart attack and vessel revascularization.
"Since the new DES arrived on the market, stenting has evolved into a multi-billion dollar industry for the stent makers and doctors and hospitals alike. According to the May 17, 2007 Wall Street Journal, "Americans spent at least $14 billion on coronary-stent procedures last year, including surgical and hospital fees."
Both J&J and Boston have received letters from Committee Chairman, Henry Waxman (D-CA), requesting documents to include correspondence with the FDA. The Committee also wants to know whether the companies used marketing funds to conduct clinical trials and how much researchers were paid and seeks information related to any adverse events revealed in the pre-approval clinical trials, as well as in post-approval use of the products.
In May 2007, after J&J announced that it would withdraw the Conor Medsystem's heart stent from the Indian market after the device failed to complete clinical trials in the US, the Drug Controller General of India raided the company's distributor's office in New Delhi and seized all existing stock of the heart stent, India's drug controller general M Venkateswarlu told the Economic Times on May 10, 2007.
The exact number of Conor stents currently on the market was still being assessed but the Times reports that thousands of patients in India could be at risk because an estimated 8,000 Indian patients have be implanted with the device.
Also the recent "Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE),"study published online on March 26, 2007, by the New England Journal of Medicine showed patients who received stents fared no better than patients who did not.
For the study, led by Dr William Boden of Buffalo General Hospital in New York, half of the roughly 2,300 patients underwent stenting procedures, took heart drugs, and were counseled to make lifestyle changes, such as losing weight, exercising, and giving up smoking and the other half received only lifestyle counseling and drugs to lower cholesterol, relax blood vessels, slow heart rate, and prevent blood clots. After an average of four and a half years, the study found a similar rate of death, heart attack, and stroke in both groups.
In an editorial accompanying the NEJM study, Dr Judith Hochman and Dr Gabriel Steg wrote: "The COURAGE trial should lead to changes in the treatment of patients with stable coronary artery disease, with expected substantial health care savings."
Experts note that there are massive profits at stake. In 2006 alone, combined J&J and Boston earned $3 billion from the devices. On December 4, 2006, Bloomberg News reported that in 2005, the new stents accounted for 52% of total sales for J&J and 43% for Boston.
In July 2007, the stent makers announced their second-quarter earnings and J&J revealed that sales of the Cypher in the US have dropped 41% from this time last year, while Boston released sales figures for its Taxus showing a drop of 42%.
In December 2006, an FDA Advisory Panel determined that off-label use, or using a stent for a purpose outside the device's approved label, is associated with an increased risk of stent thrombosis, death or heart attack compared to approved uses.
Some examples of off-label stenting include use in previously stented patients, patients with diabetes, patients who have stents placed immediately after a heart attack or patients who have stents placed in two arteries which branch off from each other.
Experts say that in the majority of cases the devices are being implanted in patients who could potentially be harmed. According to the FDA, over 60% of DES are being implanted in patients with more complex heart problems than the conditions for which the devices were approved.
With a priced tag of $10,000 to $38,000, as many as 85% of the stenting procedures are non-emergency and are being performed on people with only partially blocked arteries for the relief of recurrent chest pain, according to March 23, 2007 Associated Press.
The first DES was approved in April 2003, and by December 2006, at a hearing on the "Prospective on Drug eluting Stents: Balancing Risks and Benefits," the Advisory Panel reported that 3 out of 5 implants were for unapproved uses.
Dr Ron Waksman presented the results for Contemporary Registries of Washington Hospital Center and reported that the rates of stent thrombosis were almost doubled in cases of off-label use compared to on-label use at 30 days and at 12 months.
He also said that in general, when they looked at on-label and off-label use, "the drug eluting stents are more thrombogenic than bare-metal stents."
For both on-label and off-label use, Dr Waksman said, "over time, late stent thrombosis is seen more in the DES versus the bare-metal stents."
Dr Peter Smith of Duke University told the panel that stenting is being performed on patients with high severity coronary problems such as 3 vessel disease who should be undergoing coronary bypass grafting surgery.
He presented data that showed in these types of cases, 1 out of every 20 patients who died after treatment with stenting would have survived if coronary bypass grafting would have occurred and that DES use in patients with 3 vessel disease results in about 3,600 premature deaths annually in the US.
In the end, the panel did recommend that a warning be added to the DES labels stating that off-label use may increase the risk of thrombosis, myocardial infarction, and death, and several members recommended that a black box warning be added. However, Dr Brian Zuckerman, director of the FDA's division of cardiovascular devices, quickly quashed that idea, saying there would be no black box warning, according to MedPage Today on December 8, 2006.
But as usual, investigations have shown that the FDA was aware of the DES problems for years. Within 6 months of the approval of the first DES, the FDA had already identified 50 cases of allergic reactions and agency records show that a few months after the Cypher arrived on the market, the FDA received a cluster of sub-acute thrombosis reports and the FDA and J&J issued a letter notifying doctors of the initial reports in July 2003.
The Tarus was launched in March 2004, and on July 16, 2004, Boston announced a major recall of 85,000 of the devices after a death and serious injuries were linked to the DES, just two weeks after 200 were recalled following reports of malfunctions during implant procedures. At the time of the announcement, the company also said that it was recalling 11,000 bare metal stent systems, which the FDA found to be linked to two deaths and 25 serious injuries.
Two years later on October 23, 2006, Bloomberg reported that 2.9% of DES patients could develop clots within three years and said, "More than 4 million people have received such stents since 2001, which means clotting related to drug-coated devices may have caused as many as 20,000 heart attacks and 10,000 deaths worldwide."
The American College of Cardiology posted an editorial online by Dr Sanjay Kaul, director of the cardiology fellowship training program at Cedars-Sinai Medical Center and a colleague on October 11, 2006, that warned that blood clots in drug-coated stents may be causing an extra 2,160 deaths in the US alone each year.
The next month, on November 29, 2006 analysis by researchers at the Cleveland Clinic found the risk of blood clots was increased as much as 5-fold in patients who receive drug-coated stents compared to patients implanted with the old bare-metal stents.
"There are hundreds of thousands of Americans who are currently getting stents placed who do not need it as initial therapy," according to Dr Raymond Gibbons, professor of medicine at the Mayo Medical School and president of the American Heart Association, in a United Press International article.
In the March 28, 2007, Wall Street Journal Health Blog, Dr Andy Demajio wrote, "It has been distressing to see how interventional cardiologists have been happily stenting their patients to fatten their wallets."
"This immoral practice should come to a stop," he wrote. In May 2007, the Medicare Strike Force reported that one cardiologist had implanted 25 unnecessary stents in 2006 alone, with most procedures paid for by Medicare.
Legal experts are predicting that future lawsuits filed against Boston and J&J may well include the names of cardiologists and hospitals that helped turn the stenting for profit business into a billion dollar industry. Being there is no way to reverse the stenting procedure, patients face a life-time of worry because a blot clot in a stent can cause a stroke or heart attack without warning at any time.
Lawsuits against the stent makers continue to mount. On December 6, 2007, 46-year-old Sean O'Shea, a man who had five stents implanted, announced a lawsuit against J&J, alleging the company failed to warn him about potential blood clotting complications associated with the stents.
"Had I known there would have been this many complications," he said in a news conference, "I would have chosen other options."
On July 30, 2007, the Zimmerman Reed law firm announced the filing of a lawsuit against J&J by a Minnesota man who suffered a heart attack as a result of a blood clot at the site of his Cypher implant. According to the press release, it is estimated that over 50,000 patients have been implanted with the Cypher stent.
Subscribe to:
Posts (Atom)